|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2014/12/8 ¤U¤È 04:04:39
|
~ Ãĵؤ½§i~ ·sÃÄP1101©ó¬ü°ê¦å²G¸~½F¦~·|µoªí¡GªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)ªø®Ä®ÄªG½T»{¡A ¹F¨ì¨CӤ르¤@°w¥B°Æ§@¥Î§ó§Cªº¥Ø¼Ð - µo¥Í½t¥Ñ: ¥»¤½¥qì³]pµo©úP1101®É¡A§Y¥H¨C¤G¦Ü¥|¶g¬I¥´¤@¦¸¬°¥Ø¼Ð¡C¥»¤é¡A¥»¤½¥q±ÂÅv¹Ù¦ñ¶ø¦a§QAOP¤½¥q©ó¬ü°ê¦å²G¸~½F¦~·|(ASH MEETING)¤¤µoªíP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)¤§©µªøÁ{§É¸ÕÅç³ø§i¡A¸Ó¸ÕÅç³]p±N¨C¨â¶gµ¹ÃĤ@¦¸¥BÀø®Ä¨}¦nªºPV±wªÌ¡A¦bªvÀø¤@¦~«á½Õ¾ã¦Ü¨C¥|¶gµ¹ÃĤ@¦¸¡A¨ä¤¤³¡¤À¸ÕÅç±wªÌ¤w«ùÄòÀøµ{ªø¹F¥|¦~¡C ¸g¦¹½Õ¾ã«á¡A±wªÌ¦å²G¤¤¬õ¦å²y«ü¼Æ¤´ºû«ù¦b¥¿±`ª¬ºA¡A¥iª¾·s¤@¥Nªºªø®Ä«¬¤zÂZ¯À±µ¨ü«×§ó¦n¡C ¸ÓÁ{§É¸ÕÅç³ø§iÃÒ¹êP1101¨C¤G¦Ü¥|¶gµ¹ÃĤ@¦¸ªºªvÀø¤è¦¡½T¹ê¥i¦æ¡A³o¤]¥¿¬O¥þ²yÃĬɤ@ª½¥H¨Ó¿n·¥°l¨Dªº¥Ø¼Ð¡C - ¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¬ãµo·sÃÄ¥N¸¹©Î¦WºÙ¡GP1101 (2)¥Î³~¡GP1101«Y·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\2b)¡A²{¥¿¶i¦æ¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯gµ¥¤HÅéÁ{§É¸ÕÅç (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G²Ä¤T´ÁÁ{§É¸ÕÅç(Pivotal Trial)¡B·sÃĬdÅçµn°O¥Ó½Ð (Biologics License Application) (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G ªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\2b)(P1101)ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g±wªÌªº¥þ²y©Ê²Ä¤T´ÁÁ{§É¸ÕÅç(Pivotal Trial)¡A¸ÕÅ粺ÙPROUD-PV¡A¸ÓÁ{§É¸ÕÅç²{¥¿¶i¦æ¤¤¡C ºô§}³sµ²: http://clinicaltrial.gov/ct2/show/NCT01949805¡K - ±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G P1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅ秹¦¨«á¡A±N¦V¬ü°êFDA¤Î¼Ú¬wEMA»¼¥æ·sÃĬdÅçµn°O¥Ó½Ð(Biologics License Application)¡C A.¹wp§¹¦¨®É¶¡¡G¨Ì¾Ú¥Ø«e¦¬®×¶i«×¡AY¤@¤Á¶¶§Q³Ì§Ö¥i¦b2015¦~¤U¥b¦~»¼¥æ·sÃĬdÅçµn°O¥Ó½Ð¡A¼f¬d¶i«×±Nµø¥DºÞ¾÷Ãö¦Ó©w¡C B.¹wpÀ³t¾á¤§¸q°È¡G¥»¤½¥q±Nt³d¦V¬ü°êFDA»¼¥æ·sÃĬdÅçµn°O¥Ó½Ð¡F¼Ú¬w¦a°Ï«h¥Ñ¥»¤½¥q±ÂÅv¹Ù¦ñAOP¤½¥qt³d¦VEMA¥Ó½Ð¡C |
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2015/3/19 ¤U¤È 05:36:23²Ä 97 ½g¦^À³
|
²q·Q¤j ¨¥«¤F §Æ±æ§Ú们¥H«á³£¯àªgÃĵؤ§¥úµoÓ°] ¸É¥R¤@¤U C ¨x¤G´Á¦¬®×60¤H ÁÙ±oªá2¦~ ¤ÓºC¤F ¤½¥q¤è±»¡ «á¨Ó¦]IPO«á¤½¥q¦W®ð¤ñ¸û¦³¤F «á±±µ®×´N¶¶§Q¤F ¦ÓC¨x¨ú±oÃÄÃÒªº¾÷²v §Ú¬°¤j®a±ÀÂ_¤@¤U 1¥Ñ°ªÂ媺¸ê°T ªv·U²v¬ù9¦¨ 2¥Ñ¥x¤j³¯°|¤h¤f¤¤¤]ıªº¤£¿ù ·|¤£·|¹³¿ÕµØ¤§¿úªá25»õ¬ü¤¸²Ä¤T´Á«o¦]±wªÌªÍ³¡¥X²{¿Wª«¦Ó¥¢±Ñ£z ÁÙ¦n¦³PV¬°§ÚÌ·í«e¨® PV¦³±wªÌ¤w¸g¥ÎÃÄ2¦~¤F ÃÒ©úP1101¬O¦w¥þªº ©Ò¥HC¨x¤è±ÃÄÃÒÀ³¸Ó¤]¨S°ÝÃD ¥¼¨Ó¤@°¦¤@°¦ÃÄÃÒ°ïÅ|¤W¨Ó §Ú̪º§ë¸ê¸ò§O¤H¤ñ°_¨Ó ´N¹³¯¸¦b¥¨¤HªÓ»H¤W©¹¤Wª¦ ¤@©wª¦ªº¤ñ§O¤H°ª¤S§Ö ÃĵبC¦¸ªk»¡·|³£¦³¤@±i³æ§ÜÃĪ«hummirªº¾P°â¹Ï ¤£Ãø¬Ý¥X¤½¥q¹ïP1101ªº´Á«Ý ¦phummir¤@¦~¯à½Ä¦Ê»õ¬ü¤¸ªº¥ø¹Ï¤ß |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/3/19 ¤W¤È 11:26:18²Ä 96 ½g¦^À³
|
¦b¤£¤[ªº±N¨Ó¡AÃĵØÂåÃıN§¹¦¨««ª½¾ã¦X¡A´£¤É¤½¥q¦b°ê»ÚÂåÃĬãµo²£·~ªº¯à¨£«×¤Î¦b¥@¬ÉÂåÃĬãµo²£·~¤§¦a¦ì¡A¦¨¬°¥@¬É¤@¬y±M·~Ãļt¡C¡¨ ºK¿ý¦Û:¥xÆW¬ãµo«¬¥Í§Þ·sÃĵo®i¨ó·|(TRPMA),¥Î¨¦ºq·j´M´N¦³¤F. |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/3/19 ¤W¤È 11:23:04²Ä 95 ½g¦^À³
|
¤£¥Î»¡SORRY,¨C¤H«ä·Q¼Ò¦¡¤£¦P,¬O§_§ë¸ê,¥Ñ§ë¸ê¤H¦Û¦æ¨M©w.ªÑ»ùº¦¶^¤]¥ÑÉ]³õ¨Ñ»Ý¨M©w. É]³õ³W¼Ò,Àç¹B¼Ò¦¡,¤½¥q¯à§_¦¨¥\,¥Ñ¸³¨Æ·|³W¹º¥þÅvt³d. |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/3/19 ¤W¤È 10:39:42²Ä 94 ½g¦^À³
|
¹ï¤£°_ §õÁ`²Î¤j «e½g¤å³¹¦³«_¥Ç¤§³B ½Ð¤j¤H¤j¶q®ü²[! ¤p§Ì¨Æ¥ýÁn©ú §Ú¤£¬O¨Ó¾x³õªº ¬Q¤Ñªº©å¤å ¥u¬O§çµoÓ¤Hªº¤¤©Ê¬Ýªk ¶Q¤åªº¦r¸Ì¦æ¶¡ ¤p§ÌÁô¬ùı±o²¤¦³·Y·N ©Ò¥H¤µ¤é¦A²²¤¸ÑÄÀ ±æ¯à´î§C±zªº»~·| º¥ý´N¡¨¹ï©ó PV , ET ªº¥«³õ Ó¤H¹ê¦b«ÜÃø¦ôp¦³¦h¤Ö ¡§ ³o¬OÓ¤H¯à¤O¦ô¤£¥X ¦Ó¤£¬O»¡¥¦Ìªº¥«³õ«Ü¤p ¤½¥q¤£¬O¤]´¿¥H Jakafi ªº°â»ù ¨Ópºâ¼ç¦b¥«³õ¶W¹L¦Ê»õ¬ü¤¸¶Ü? ¨ä¤G Jakafi ªº°Æ§@¥Î¤£¤Ö ³o¬O P1101 ¦b PV , ET ¥«³õªºÀu¶Õ ¦Ü©ó ¡§ ±ÂÅvµ¹ AOP ªº³¡¥÷ Ãĵئb(Åv§Qª÷ + ÃÄ«~¥Í²£¥N¤u¶O)ªºÀç¯q²v¬ù¦b20 ~ 25 % ¡¨ §Ú¬O³o¼Ë¦ôpªº §Ú´¿ ¸g¥Ñ³ø¾ÉÅ¥»DªLÁ`»¡ ÃĵئbÅv§Qª÷©MÃÄ«~¥Í²£¥N¤u ¥iÀò¤T¦¨ ¥Ñ°]³ø¦ôºâ Ãĵؽ浹 AOP ªº¤ò§Q²v ¬ù¦b 70 ~ 75 % °²³]Åv§Qª÷¬O 10% ¨º 20 % ´N¬O¥N¤u¶O ©Ò¥H¥N¤u©Ò±o 20 % * (0.7 ~ 0.75) = 14% ~ 15 % Á`¦@ÃĵØÀò§Q¬ù¦b 24 % ~ 25 % ¦A¦©±¼ºÞ¾PÂø¶O ©Ò¥H §Ú¦ô 20% ~ 25 % ´N®³¤½¥q»¡ªº PV 10 »õ¬ü¤¸ ¨Ó¦ôºâ (°²³]¬ü°ê¥«³õ 5»õÄݦ۾P) 5*30*0.225 + 5*30*0.3 = 78.75 ( 0.225 ¬O 20 ©M 25 ªº¥§¡È , 0.3 ¬O¦Û¾PªºÀç¯q²v ) ET Y¤]¦ô10»õ ¤GªÌ´Nªñ160»õ¥x¹ôªºÀò§Q Y¦A¥[B C¨x¤Î¨ä¥L«~¶µ ¥¼¨Ó«e´º©Î¤j¥i´Á«Ý ÁöµM¤p§Ì¥Í©Ê¤ñ¸û«O¦u ¦ý¤]¹ï¥¦ªº¼ç¦bÃzµo¤O«Ü¦³´Á«Ý ©Ò¥H§ë¸ê¥H«Ý §Ú¦Û»{¨S¯à¤O³oÀÉ°µ§¹´«¥tÀÉ ¥u¯à±N¦Û¤vªºµû¦ô§@¸êª÷¤ñ¨Òªº°t¸m ¤½¥q¥Ø«eÀ³¸Ó¥[ªoªº¬O ¥xÆW¸¹ºÙ¨x¯f¤ý°ê ¤S¦³¨x¯fÅv«Â¥D¨Æ C ¨x¤G´Á¦¬®×60¤H ÁÙ±oªá2¦~ ¤ÓºC¤F ³oªí¥Ü«Å¶Ç¤£¨¬ ³Ì¦³¤Oªº«Å¶Ç¤è¦¡¤§¤@ ´N¬O¥«È©Ô°ª ´CÅé±N¤£½Ð¦Û¨Ó¦a³ø¾É ¦¬®×³t«×À³·|¥[§Ö ¦p¤ÍªÑ¯E¹©µM ³o¬O¤@Á|¦h±oªº¨}©Ê´`Àô¤è¦¡ ·íµM¤½¥q¤£¯àª£§@ªÑ»ù ¦ý¤]À³Á٨䥻½è¤~¬O! Ó¤Hı±o²{¶¥¬qÃĵبS¤H®ð ¬O«Ü¦h¦]¯À¨ÏµM ¦p¦óÅý§ë¸ê¤j²³§ó¤F¸ÑÃÄµØ À³¤]¬O¤½¥q¸Ó§V¤Oªº¤è¦V¤§¤@ ¦Û§U¤~¯à¤H§U ¤£¬O¶Ü? Åý¤p§Ì¦b«¥Ó¤@¦¸ «e¤å§Ú¤£¬O¦b°Û°IÃÄµØ ´N¦p¤p^¤jèè©Ò¨¥ ¡§¥ð®§µ¥«Ý¬O¬°¨«§ó»·ªº¸ô, ¦b¤£¤[ªº±N¨Ó¡AÃĵØÂåÃıN§¹¦¨««ª½¾ã¦X¡A´£¤É¤½¥q¦b°ê»ÚÂåÃĬãµo²£·~ªº¯à¨£«×¤Î¦b¥@¬ÉÂåÃĬãµo²£·~¤§¦a¦ì¡A¦¨¬°¥@¬É¤@¬y±M·~Ãļt¡C¡¨ ¤p§Ì¤]¬Æ¬°´Á«Ý ¤j®a§ë¸ê³£¤j¦¨¥\ ÂIªÑ«°ª÷ ÁÂÁ¤j®a! |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2015/3/18 ¤U¤È 06:39:31²Ä 93 ½g¦^À³
|
¥»¤H¹ïÃĵؤÀªR¥¦ªº¥¼¨Ó ¨S¦³°¾³R ¥uºâ¬O¼ÖÆ[°¾¶È·V ¤]¬O®Ú¾Ú¤p§Ì¦¬¶°¤@¨Ç°T®§ µ¹¦Ñ±¤Õ¤@¨Ç°Ñ¦Ò ·íµM§ë¸ê·ÀI¦Ût ´N¹³·í¥X§Ú¥H¥Í²£JAKAFI¤½¥q¬O¥«È¬O50»õ¬ü¤¸ ¨Ó»¡ÃĵؤWº¦¬O¦³¥»ªº §Ú·íµMª¾¨ì¥¦ªº¥«È¤w¸g130»õ¬ü¤¸ ¦ýÁÙn©ÈÀ~¨ì¥xÆW¤H ¥u»¡50»õ¬ü¤¸ §A¥i¥H»¡¤zÂZ¯Àn³Q²^¨O¤F ¨º·íµM»°§Ö½æ §A¦pªGı±oÃĵئ³§Æ±æ ¨º§Æ±æ¤j®a¤@°_ÁȤ@¸ô©ê¨ì*000¤¸ ·íµM¬Ý¨ì²{¦bªÑ»ù®Ú¥»»¡§ÚºÆ¤F ¦ýô¦³¤£¦P¨£¸Ñ §Ú¤£§Æ±æ¾a¨u¯fÁȤj¿ú ©h¥B·§²¤¦ô¤@¤U ¤j®aª¾¹D¥xÆW¬O¨x¯f¤ý°ê ¥HÃĵØC¨x¤G´Á¦¬®×60¤Hªá2¦~¨Ó¿Å¶q PV 256¤H¦¬®×17Ó¤ë PVªº¥ÎÃĻݨD¬OÄÈ´÷ªº §Ú¤jÁx¦ô«Ü¦³¥i¯à¶W¹L20»õ¬ü¤¸ ¨ä¥L§Ú³£·í½æ¤£¥X¥h0 ´N¥H³o°¦¨ä¥L¬°0 Ãĵإ¼¨Ó¦³¾÷·|*000¤¸ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/3/18 ¤U¤È 12:57:38²Ä 92 ½g¦^À³
|
¥»¨Ó¬O¤£·Q¦b³oÓª©±¦A»¡¨Ç¤°»ò ÀRÀR¦a§bµ¥´N¦n ¤p§Ì©M¤j³¡¤Àªº¤j¤j¤@¼Ë «ùÄò¦a©êµÛ ¦³¨Ç¤j¤j©Î³\¦³§ó¦n¼Ðªº °ª»ù´N²¾±¡¤F ²{¦bªºÃĵؤ£¬O°ò¥»±ªº°ÝÃD ¦Ó¬O¨S¦³¦³¤O¤H¤hªº©ï·R ©¹©¹§Q¦h¤@¨Ó´N¥XºÉ¤F ¤p§Ì¹ï¤@ÀɪѲ¼ªº¬Ýªk ¦V¨Ó´N¦Û¤v©Òª¾ªº ¹ê¸Ü¹ê»¡ µLª¾»¡¿ùªº ´N¥u¯àPºp¤F ¦Û¤vªºµû¦ô ·|ÀHµÛ®É¶¡ªº±À²¾ ©Î¹ï°ò¥»±ªº¶i®i¤Î¤F¸Ñ ¨Ó½Õ¾ã¦Û¤vªº«ùªÑ°t« ¤µ¤Ñ¤p§Ì·Q¦b¦¹ªí¹Fªº µLÃö¦hªÅ ¬O¤p§Ì¨p©³¤Uªºµû¦ô ´N¹³§õÁ`²Î¤j¥Î3008ªº·s»D¨Ó¤ÀªRÃĵؤ@¼Ë °²¦p¥H¤U¬Ýªk©M§õÁ`²Î¤j¦³¬Û¥ªªº¦a¤è ½Ð§õÁ`²Î¤j®ü²[ ¹ï©óPV , ET ªº¥«³õ Ó¤H¹ê¦b«ÜÃø¦ôp¦³¦h¤Ö Jakafi §Ú¤£ª¾¦~½æ¦h¤Öª÷ÃB ²{¦bªºÀç·~ÃBÀ³¥HªvÀøMF¬°¥D ¡§Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis (MF), including primary MF, post¡Vpolycythemia vera MF, and post¡Vessential thrombocythemia MF.¡¨ ¸`¦Û http://www.incyte.com/jakafi MF¬OP©R©Ê¯e¯f ÁöµM Jakafi¦³¤£¤Ö°Æ§@¥ÎLow blood counts , Infection , Skin cancers ÁÙ¦³anemia, low platelet count, bruising, dizziness, headache µ¥ ¦ý¹ï¥Í©R¥æÃöªº±wªÌ¤´±o¨Ï¥Î ¨Ó©µªø¥Í©R ²{¦b§ÚÓ¤H¬Û«H °²YP1101¯à¦¨¥\ ¹ï PV , ET ³o¨â¶ô¥«³õÀ³¬O¦³Ävª§¤Oªº °ÝÃD¦b©ó¦h¤Ö¤H·|¨Ï¥Î¦Ó¤w ´N¹L¥hÃĵش¦ÅSªº°]³ø ¥b²q¥b¤ÀªR ±ÂÅvµ¹AOPªº³¡¥÷ Ãĵئb(Åv§Qª÷ + ÃÄ«~¥Í²£¥N¤u¶O)ªºÀç¯q²v¬ù¦b20 ~ 25 % Y¦Û¤v¶}ÂX¥«³õ³¡¤À ´N¤£©ö¦ôp¤F ¦Ü©óB C ¨x Roche ªø®Ä«¬¤zÂZ¯À Pegasys 2014 ¾P°â¹êÁZ ÁÙ¯à¹F10»õ¬ü¤¸ ¦bGilead µ¥¤½¥q C ¨x·sÃıj¶Õ§ð¦û¥«³õ ¥u®ø°h20 % ÁÙºâ®t±j¤H·N ¤£¹L ©Î³\¤´±o¬Ý2015ªºª¬ªp ¦]¬°2014ªº·~ÁZ À³¦³³¡¤À¨Ó¦Û2013¦~±wªÌ ¦]Àøµ{©|¥¼µ²§ô¦Ó«ùÄò¥ÎÃÄ©Ò±a¨Óªº ¨Æ¹ê¤W ³o¦¸ªk»¡·| ¤p§Ì½Ð¤F¤p¤ü¥hÅ¥ ¨Ã°Ý¤F¤@Ó°ÝÃD(·|¥~°Ýªº) ¤zÂZ¯ÀªvÀøC¨x ªF¦è¤è¤HºØªºÀø®Ä¦³µL®t²§ ? ¤½¥q¦³µL¤åÄm¥i´£¨Ñ°Ñ¦Ò ¸â¸³ªº¦^µª¬O ¥Ø«e¤´¥¼¦³©w½× ¤£¹L¨Ì¤½¥qªº¸ê®Æ ªF¤è¤HÀø®Ä¸û¨Î ¹L¥hªLÁ`¦b±µ¨üÂø»x±M³X®É ³zÅS¤½¥q©Î±N¥H§C»ùµ¦²¤¨Ó·m¦û¨È¬w¥«³õ Ó¤H¹ï¦¹¤ñ¸û¦³´Á«Ý ¦ý¥¼¨Ó·|¦p¦óµo®i ¥u¯àµ¥«ÝÀRÆ[¨äÅܤF ¥H¤W»¡ªk ¶È¨Ñ°Ñ¦Ò ¨Ã½Ð«ü±Ð ¦³¤@½g¤ñ¸û¦Ñªº¤å³¹(2011ªº) ¦b»¡¤zÂZ¯À The renaissance of interferon therapy for the treatment of myeloid malignancies http://www.bloodjournal.org/content/117/18/4706.long?sso-checked=true ¦³¿³½ìªº¤j¤j¥i¥H«e©¹°Ñ¦Ò ÁÂÁ¤j®a! |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2015/3/5 ¤U¤È 01:53:10²Ä 91 ½g¦^À³
|
§Ç¸¹ 1 µo¨¥¤é´Á 104/03/05 µo¨¥®É¶¡ 13:33:49 µo¨¥¤H ªL°êÄÁ µo¨¥¤H¾ºÙ Á`¸g²z µo¨¥¤H¹q¸Ü 02-26557688 ¥D¦® ¤½§i¥»¤½¥q±N©ó104¦~3¤ë6¤é¥l¶}ªk¤H»¡©ú·| ²Å¦X±ø´Ú ¡@²Ä 30 ´Ú ¨Æ¹êµo¥Í¤é 104/03/06 »¡©ú ²Å¦X±ø´Ú²ÄXX´Ú¡G30 ¨Æ¹êµo¥Í¤é¡G104/03/06 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G104/03/06 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G15 ®É 00 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡GKGI³Í°òÃÒ¨éÁ`³¡¤j¼Ó ¥x¥_¥«©ú¤ô¸ô700¸¹12¼Ó 4.ªk¤H»¡©ú·|¾Ün°T®§¡GÃĵØÂåÃIJ£«~¶}µo¶i®i¤À¨É 5.ªk¤H»¡©ú·|²³ø¤º®e¡G¤º®eÀɮשó·í¤é·|«á¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸ 6.¤½¥qºô¯¸¬O§_¦³´£¨Ñªk¤H»¡©ú·|¤º®e¡GµL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡G©ó14ÂI30¤À¶}©l³ø¨ì¤Î»â¨ú¸ê®Æ |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/3/5 ¤U¤È 12:00:49²Ä 90 ½g¦^À³
|
¥»¤½¥q±N©ó104¦~3¤ë5¤é°Ñ¥[¤¸´IÃÒ¨éÁ|¿ì¤§¡u¤¸´IÃÒ¨é2015Á`Åé¸gÀٽ׾º[²£·~ÁͶձ´°Q¬¡°Ê¡v¡C ´Á«Ý¦³¦nªº®ø®§»P¶i«×. ¥[ªo! |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2015/3/5 ¤W¤È 10:36:36²Ä 89 ½g¦^À³
|
¥»¸ê®Æ¥Ñ¡@(¿³Âd¤½¥q) ÃĵØÂåÃÄ¡@¤½¥q´£¨Ñ §Ç¸¹ 1 µo¨¥¤é´Á 104/03/04 µo¨¥®É¶¡ 16:40:29 µo¨¥¤H ªL°êÄÁ µo¨¥¤H¾ºÙ Á`¸g²z µo¨¥¤H¹q¸Ü 02-26557688 ¥D¦® ¥»¤½¥q¨üÁÜ°Ñ¥[¤¸´IÃÒ¨é©ó104¦~3¤ë5¤éÁ|¿ì¤§¡u¤¸´IÃÒ¨é2015Á`Åé¸gÀٽ׾º[²£·~ÁͶձ´°Q¬¡°Ê¡v ²Å¦X±ø´Ú ¡@²Ä 30 ´Ú ¨Æ¹êµo¥Í¤é 104/03/05 »¡©ú ²Å¦X±ø´Ú²ÄXX´Ú¡G30 ¨Æ¹êµo¥Í¤é¡G104/03/05 1.¥l¶}ªk¤H»¡©ú·|¤§¤é´Á¡G104/03/05 2.¥l¶}ªk¤H»¡©ú·|¤§®É¶¡¡G15 ®É 45 ¤À 3.¥l¶}ªk¤H»¡©ú·|¤§¦aÂI¡G¥x¥_¥«´°¤Æ«n¸ô¤G¬q97¸¹¤¸´IÃÒ¨é11F 4.ªk¤H»¡©ú·|¾Ün°T®§¡G¥»¤½¥q±N©ó104¦~3¤ë5¤é°Ñ¥[¤¸´IÃÒ¨éÁ|¿ì¤§¡u¤¸´IÃÒ¨é2015Á`Åé¸gÀٽ׾º[²£·~ÁͶձ´°Q¬¡°Ê¡v¡C 5.ªk¤H»¡©ú·|²³ø¤º®e¡G¤º®eÀɮשó·í¤é·|«á¤½§i©ó¤½¶}¸ê°TÆ[´ú¯¸ 6.¤½¥qºô¯¸¬O§_¦³´£¨Ñªk¤H»¡©ú·|¤º®e¡GµL 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ¡GµL |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2015/3/4 ¤U¤È 10:18:45²Ä 88 ½g¦^À³
|
¬£Ã¹ªY¡C¹ï©ó¤A¨x©M¤þ¨x ¬£Ã¹ªY°Ï°ì¾P°â ¬ü°ê---- 194 --- 307 ---- -36 --- 19 --- 23 ¼Ú¬w----------- 236 --- 356 ---- -33 --- 23 --- 27 ¤é¥»------------ 60 --- 52 ---- 28 --- 6 --- 4 °ê»Ú---- 525 --- 597 ---- -8 --- 52 --- 46 Á`¾P°âÃB----- 1015 --- 1312 --- -20 --- 100 --- 100 ²Ä1ÓÄæ°Ï°ì§O 2014¦~¾P°âÃB²Ä2Ó¬W¡]mCHF¡G¦Ê¸U·ç¦¡^ 2013¾P°âÃB²Ä3Ó¬W¡]mCHF¡G¦Ê¸U·ç¦¡^ ²Ä4ÓÄæ¢HªºÅÜ¤Æ ²Ä5Ó¦C2014¦~°Ï°ì¦û¤ñ¡]¢H¡^ ²Ä6Ó¦C2013°Ï°ì¦û¤ñ¡]¢H¡^ ¾P¶q¤U°20¢H¡A¥Dn¶°¤¤¦b¬ü°ê©M¼Ú¬w¡A¥Ñ©ó¨Ó¦Û·s¤@¥N¤þ«¬¨xª¢ªvÀøªºÄvª§¥[¼@¡C ¦b°ê»Ú°Ï¡A¦³¥Íªø¦b©Ô¤B¬ü¬w¡]+ 6¢H¡^¡A¥Ñ©ó¤½¦@³¡ªùªº¾P°â¡A¸û§Cªº¾P°â¦bªF¼Ú©è®ø¡A ¤¤ªF©M«D¬w¦a°Ï¡C¦b¤é¥»¾P°â¤]¦³©Ò¼W¥[¡A¥Ñ©ó¦b¤T«²Õ¦XÀøªk¨Ï¥Î¶q¼W¥[¡C ºK¦Û2014¦~ù¤ó¤½¥q°]°È³ø§i |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/3/4 ¤U¤È 08:47:31²Ä 87 ½g¦^À³
|
Roche ªø®Ä«¬¤zÂZ¯À Pegasys 2014 ¾P°â¹êÁZ ¨Ñ¤j®a°Ñ¦Ò ¤p§Ì¤£°µµû½× ½Ð¤j®a¦Û¦æ¸ÑŪ ÁÂÁÂ! Pegasys. For hepatitis B and C. Pegasys regional sales United States ---- 194 --- 307 ---- ¡V36 --- 19 --- 23 Europe ----------- 236 --- 356 ---- ¡V33 --- 23 --- 27 Japan ------------ 60 --- 52 ---- +28 --- 6 --- 4 International ---- 525 --- 597 ---- ¡V8 --- 52 --- 46 Total sales ----- 1,015 --- 1,312 --- ¡V20 --- 100 --- 100 ²Ä 1 Ó column °Ï°ì§O ²Ä 2 Ó column 2014 ¾P°âÃB (mCHF: millions of Swiss francs) ²Ä 3 Ó column 2013 ¾P°âÃB (mCHF: millions of Swiss francs) ²Ä 4 Ó column % change ²Ä 5 Ó column 2014 °Ï°ì¦û¤ñ ( % ) ²Ä 6 Ó column 2013 °Ï°ì¦û¤ñ ( % ) Sales decreased by 20%, mainly in the US and Europe, due to increased competition from a new generation of hepatitis C therapies. In the International region, there was growth in Latin America (+6%) due to public sector sales, offset by lower sales in the Eastern Europe, Middle East and Africa region. Sales in Japan also increased, due to increased usage in triple combination therapy. ºK¦Û 2014 Roche °]°È³ø§i http://www.roche.com/fb14e.pdf |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/3/4 ¤U¤È 05:30:17²Ä 86 ½g¦^À³
|
6446¡¦ story ¦¨¥ß©ó¤GOO¤T¦~ªºÃĵØÂåÃÄ¡A¦´Á¥Ñ©ó¨â¬£ªÑªF·N¨£¤£¦X¡A³s¤jªÑªF°êµo°òª÷³£»P¸gÀç¹Î¶¤¹ï綠°ó¡A¬Æ¦Ü¹ï¥Lªº¸gÀç¯à¤O¤@«×·P¨ìÃhºÃ¡A¥[¤W·sÃĬãµoÃm¤é¶O®É¡A¤½¥qµLªkÀò§Q¡A¦]¦¹¨C¦~ªÑªF·|Á`¬O¤£¤Ó¦w¹ç¡A³Ì¿E¯Pªº¤@¦¸¥X²{¦b¤GOO¤E¦~¤C¤ë¡A·í®ÉÃzµo©xªÑ»P¥ÁªÑ¨â¬£¶Õ¤O¿E¯P½Ä¬ð¡AÅýªL°êÄÁ§xÂZ¤£¤w¡C ±¹ï³o¨Çª§ºÝ¡AªL°êÄÁ¤T¤Ñ¨âÀY´Nn¶]ªk°|¡A¤£Â_³B²z¨Ó¦Û¥|±¤K¤èªº¶Â¨ç§ðÀ»¡AÁÙn¦w¼¾¸gÀç¹Î¶¤¡AÅý³o¦ì²¦¥Í³£¦b°µ¬ãµoªº¬ì¾Ç®aµL©`¦a»¡¡A¡u¦^¥xÆW¡A¯u¦aÅý§Ú¾Ç²ß«Ü¦h¡C¡v ¤£¹L¡A³Ìªñ¨â¦~¡AÃĵØÀç¹B³vº¥¨B¤J©Z³~¡A·sÃĬãµo¦¨ªG·U¨Ó·U¦n¡AÀHµÛªÑ»ù¨«°ª¡A«Ü¦hªÑªF³£¥´¹q¸Ü©Î¬Æ¦Ü·í±¨ì¤½¥q¹DÁ¡A¤@¦ìªÑªFÁÙ¤ßÃh·P©À¦a¸ò¥L»¡¡A¡u¦]¬°§Aªº§Ô°d»P°í«ù¡A§JªA¤F¨º»ò¦h§xÃø¡A¤~ÅýÃĵب«¥X¤µ¤Ñªº§½±!¡v ªL°êÄÁ¦^¾Ð¡A¤@¤E¤E¤C¦~¥L¦b Biogen¤½¥q¤u§@®É¡A·í®É¸gÀÙ³¡¦¸ªø¤¨±Ò»Êu¬ü°êBiogen¤½¥q°ÑÆ[¡A±µ«Ý¥LªºBiogen°õ¦æªø¨Ó¦Û¼w¦{»ö¾¹¡A´£¨ìBiogen¤½¥q¤w¦¨¥ß¤Q¤C¦~¡A¤@ª½¬OÁ«·l¡A»P¥L¹L¥h¦b¥b¾ÉÅé·~ªº¸gÅç¬Û·í¤£¦P¡C ªL°êÄÁ»¡¡A·í®É¤¨±Ò»Ê´N§i¶D¥L¡A¡w¥xÆW¦pªGn§ë¤J·sÃĬãµo¡AÁZ®Ä¤@©w¤£·|¦b¥Lªº¦¸ªø¥ô¤º¬Ý¨ì¡A¦ý¥xÆW¦b¹q¤l·~¤w¦³«Ü¦nªº¦¨ÁZ¡AÀ³¸Ó¿n·¥±À°Ê§óªø½u¥¬§½ªº¥Í§Þ·sÃIJ£·~¡C¡x«á¨Ó¡A¹j¤F¤@¦~¥b¡ABiogen¬ãµoªº·sÃijq¹L¬ü°êFDA(¹«~ÃÄ«~ºÞ²z§½)®Öã¡A¹j¦~¤@¤W¥«¡A·sÃĦ~¾P°âÃB´N¥ß¨è½Ä¨ì¤Q»õ¬ü¤¸¡C ¦b¬ü°ê²Ö¿n¶}µo·sÃĸgÅç«á¡AªL°êÄÁ¬°¤F¦^¥x³Ð·~¡A«e«á¦^¥xÆW¥|¤Q´X½ë¡A¤GOO¤T¦~¡A²×©ó¤U©w¨M¤ß¡A»P´XÓ®a®x¤@°_¦^°ê³Ð¥ßÃĵØÂåÃÄ¡C¤½¥q¨ú¦W¡uÃĵءv¡A´N¬O§Æ±æ¯à°÷¦¨¥\¥´³y¤@®a¥ÑµØ¤H¸gÀ窺¥@¬É¯ÅÃļt¡CÁöµM¤j®a³£¦³³Ð·~ªº¤ß²z·Ç³Æ¡A¦ý¦^·QÃĵتºµo®i¡AªL°êÄÁı±oÁÙ¬O¤ñ·Q¹³¤¤Á}¨¯¦n´X¿¡C ¦ýÃø¯à¥i¶Qªº¬O¡A§Y¨Ï±¹ï³o»ò¦hªi§é¡AÃĵتº¬ãµo¸}¨B¤@ª½¤£´¿ÃP¾Ó¡A¤Q¦~¨Ó¤@¨B¤@¨B¦a«Ø¥ß·sÃĬãµo¤ÎÁ{§É¹êÅç°ò¦¡CÃĵظ³¨Æªø¸â«C¬h»¡¡A¦³´X¦¸¦o¾D¨ü¤£¥Õ¤§Þ¡A¯uªº¬O¤ß¦Ç·N§N¡A«Ü·Q¥Ì¯ÜÃ㾤£·F¦^¬ü°ê¡A¦ý«o¦]¬°¹Î¶¤©¼¦¹¹ªÀy¥´®ð¡AÅý¦o¨M©wÄ~Äò¼µ¤U¥h¡C °í«ù¤£Â_§ë¤J¬ãµoªºµ²ªG¡A¾¨ºÞ¦³¨Ç²£«~¹J¨ì²~ÀV¡A¦ý²×¨sÅýÃĵاä¨ì¤@Ó·s¤è¦V¡C¤GOO¤E¦~¡AÃĵض}±Ò¤Fªø®Ä«¬¤zÂZ¯À·sÃÄP1101¦b¼Ú¬wªº¯u©Ê¬õ¦å²y¼W¥Í¯g(²ºÙPV)Á{§É¹êÅç¡A¤@¸ô°µ¨ì¥Ø«eªº¤T´ÁÁ{§É¡A¦Ó¥B¥Ñ©ó¦¨®Ä«Ü¦n¡A¥h¦~¤E¤ë¡A¬ü°êFDA¤]¦P·NÃĵإi¥H¥Î¼Ú¬wªºÁ{§Éµ²ªG¨Ó¬ü°ê¥Ó½ÐÃÄÃÒ¡A³oÓ«¤jªº¦¨ÁZ¡A¤£¶ÈÅýÃĵتѻù³sµf¤jº¦¡A§ó¦]¬°§K°µ¬ü°ê¤T´ÁÁ{§É¹êÅç¦Ó¬Ù¤U¤jµ§¤ä¥X¡AÃĵتº¬ãµo¹ê¤O²×©óÅý¥~¬É¬Ý¨£¤F¡C Ãĵئb¼Ú¬wªº¦X§@¹Ù¦ñAOP Orphan Pharmaceuticals(¶ø¦a§Q±M·~©t¨àÃĤ½¥q)¡A¬OÃĵطsÃÄP1101¯à°÷¨ú±o«¤j¶i®iªºÃöÁä¹Ù¦ñ¡C¦^¾Ð»PAOPªº¦X§@¡AªL°êÄÁ¤]¤£¸Tı±o¡A¹Lµ{¥Rº¡¤F¾÷½t¥©¦X¡AÅý©¼¦¹§ó¥[´i´i¬Û±¤¡C ¤GOO¤K¦~¤Q¤ë¡AªL°êÄÁ·í®É±aµÛ´X¦ìÃĵØû¤u¡Au¼w°êªkÄõ§JºÖªº¼Ú¬wÃÄ«~®i°Ñ®i¡A·í®ÉªL°êÄÁ¯¸¦bÅu¦ì«e¡A¤@¦ì¥ý¥Í®³µÛAOP¤½¥q°õ¦æªøªº¦W¤ù¡A¨«¹L¨Ó¸ò¥L»¡¡A¥L·Q¶RÃĵتº¤zÂZ¯À¡A·í®ÉªL°êÄÁ¤ß·Q¡A¡uAOP¨ì©³¬O¤°»ò¤½¥q?¥L»¡ªº¬O¯uªºÁÙ¬O°²ªº?¡v ¨º¦~ªº¤Q¤@¤ë¡AªL°êÄÁ¤S±a¶¤¥h®ü¼w³ù°Ñ®i¡A³o¦ìAOP°õ¦æªøRudolf Widmann(ÃQ°Ò)³Õ¤h¤S¨Ó¤F¡A¦A¦¸ªí¹Fn¶RÃĵتº¤zÂZ¯À¡A¦Ó¥BºA«×§ó¥[°í©w¡C©ó¬OªL°êÄÁ¸ò¥L»¡¡A¡u¦pªG¯uªº·Q¦X§@ªº¸Ü¡A¨º´N¥ý¸¨ì¥xÆW°ÑÆ[¤@¤U¡AÅý©¼¦¹¦³§ó²`¤Jªº¤F¸Ñ¡C¡v ÃQ°Ò«á¨Ó«KºV©w¤GOO¤E¦~¤G¤ë¸¨Ó¥xÆW¡A¦ý쥻¥u·Q«Ý¤@¤Ñ¡AÁÙ¯S§O¬D¿ïµØ¯è¤@¯Z¦¤W¨ì¥xÆW¡B±ß¤W´N¸¨«ªº¯è¯Z¡AªL°êÄÁ´N¸ò¥L»¡¡A¡u¤£¦æ¤£¦æ¡A¬JµM¨Ó¤F¡A¦Ü¤Ön«Ý¤T¤Ñ¡A©MÃĵثn¥DºÞ³£¨£Ó±¡A¨Ã»P¥xÆW¦å²GÅv«ÂĬ¯q¤¯³Õ¤hµ¥±M®a¦h²á²á¡A¤F¸Ñ¥xÆW¦b¥Í§Þ·sÃIJ£·~ªº¹ê¤O¡C¡v ¦bÂù¤è¬¢½Í¶¶§Qªº±¡ªp¤U¡AAOP¦b¤GOO¤E¦~±qÃĵبú±oP1101±ÂÅv¡A¨ÃÀ³¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(²ºÙPV)¡A³o¬O¤@Ó¸û¨u¨£ªº©t¨àÃÄ¡A¦ý§Y¨Ï¬O©t¨àÃÄ¡A¥þ²yPV±wªÌ¤]¦³¬ù¤O¸U¤H¡A¨ä¤¤¼Ú¬w¥e¤F¤Q¤¦Ü¤GO¸U¤H¡A¬ü°ê¤]¦³¤Q¤¦Ü¤Q¤»¸U¤H¡C ªL°êÄÁ©Z¸Û¡A쥻ÃĵاâP1101ªº¶}µo«¤ß©ñ¦b¨x¯f¤W¡A¤£¤Óª`·N¨u¨£¯e¯f¡A¦ýAOPÅýÃĵØÂಾ¬ãµo¤è¦V¡A¤Ï¦Ó¨«¥X¤@Ó·N¥~ªºÅå³ß¡C¦p¤µ¡AP1101¦b¼Ú¬wªº¤T´ÁÁ{§É¹wp¤E¤ë©³¥H«e¦¬®×§¹¦¨¡A¹wp©ú¦~¤C¤ë¦V¼Ú·ùªº¼Ú¬wÃĪ«ºÞ²z§½(EMA)¤Î¬ü°êFDA´£¥XÃÄÃҥӽСC ¥h¦~¤E¤ë¡AÃĵØÅw¼y¤Q·³¥Í¤é¡AÁܽФFAOP´X¦ì«n¥DºÞ¨Ó¤@°_Åw¼y¡A¨ä¤¤AOPªº¨Æ·~µo®i³B³Bªø¡B¥»¤H¤]¬OÂå¥Íªº³ìªv¶O³·(George Fisher)´N»¡¡A¡wP1101¬O¥L¤G¤Q´X¦~¨Ó¡A¬Ý¹L³Ì¨S¦³·ÀIªºpµe¡A¬O³Ì¯Âªº¤zÂZ¯À¡A¥¼¨Óªº¾÷·|»P«e´º¤]¬O³Ì¥i¥H¹w´úªº¡C¡x ¥Ñ©ó¬ãµo¦¨ªGÂ׺ӡAªL°êÄÁ¤]¬°Ãĵس]©w§ó°ªÃø«×ªº¬D¾Ô¥Ø¼Ð¡C°£¤F©ú¦~¤C¤ëÃĵØn¥Ó½Ð¼Ú·ù¤Î¬ü°êÃÄÃÒ¥~¡A©ú¦~¤K¤ë¦ì©ó¤¤³¡¬ì¾Ç¶é°ÏªºGMP³J¥Õ½è·sÃÄÃļt¡A¤]·|¦P¨B±Ò°Ê¼Ú·ù»P¬ü°êªº¬d¼t¾÷¸m¡A¥Ñ©ó³J¥Õ½èÃļtªº¥Í²£«~½è»P¨}²vÃø«×¬Û·í°ª¡A³oÓ¶W°ª¥Ø¼Ð¦p¤µ¤w·d±oÃĵؤ@¦Ê¦h¦ìû¤u¤H¥õ°¨Â½¡A¨C¤Ñ³£n»P®É¶¡Áɶ]¡C ¥Ñ©ó³J¥Õ½èÃļtªº¥Í²£Ãø«×°ª¡A§Y¨Ï°ê»Ú¶¡¦¨¥\ªº®×¨Ò¤]¤£¦h¡A¬°¤F§l¦¬°ê»Ú¶¡³Ì¦nªº§Þ³N»Pknow-how¡AªL°êÄÁ½Ð |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2015/3/2 ¤U¤È 03:03:51²Ä 85 ½g¦^À³
|
ÃĵØÃÄPV·sÃÄ ©é©ú¦~¤W¥« ÃĵØÃÄ(6446)·sÃĶ}µo¶i«×¤jÀò±¶³ø¡I¥Ø«e¤£¶È¤w¦³5Ó·sÃĶi¤J¤T´ÁÁ{§É¡A«i¹Ü·sÃÄÃþªÑ¤§«a¡A³Ì¨üÃöª`ªº¬O¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)ªºP1101¡A¾Ú¶Çªñ´Á§¹¦¨¤T´Á¦¬®×¡A³Ì§Ö±N¤À§O©ó¤µ¦~9¤ë©M©ú¦~3¤ë¤À§O¦V¼Ú·ù©M¬ü°êFDA¥Ó½ÐÃÄÃÒ¡A2016¦~¤W¥«¶}½æ¡A·m§ð¨C¦~¦Ü¤Ö10»õ¬ü¤¸ªºPV¥«³õ¡C ¡@¡@ªk¤Hªí¥Ü¡AP1101·sÃĤT´ÁÁ{§É¦¬®×¼Æ¬°256¤H¡A¥Ñ©ó¬O±Ä¶}©ñ©ÊÁ{§É¡A«Ü®e©ö¤ñ¹ï¨ä¦³®Ä©Ê¡CY3¤ë§¹¦¨¦¬®×¡A¥b¦~«á§Y¯à¦V¼Ú·ù¥Ó½ÐÃÄÃÒ¡A¦Ó¬ü°êÁö¤£¥Î¦A°µ¤T´ÁÁ{§É¡A¦Ó±Ä¥Î¼Ú·ù¼Æ¾Ú¡A¦ý¨äÁ{§É´Á¬°¤@¦~¡A¦]¦¹¡AYµLªk©M¼Ú·ù¦P¨B¡A©ú¦~3¤ë¤]¥i¥Ó½ÐÃÄÃÒ¡C ¡@¡@¤£¹L¡A³q¹L¼Ú·ùEMA»{ÃÒ«á¡A¥Ñ©ó¼Ú¬w°ê®aÁÙ¬On¦U¦Û¥Ó½Ð¦U°êªº¤W¥«³\¥i¡A¦]¦¹¡A¥H®Éµ{±Àºâ¡A¼Ú¬üªº¤W¥«¶}½æ®É¶¡ÂI®t¤£¦h¡C ¡@¡@¬°¤F·Ç³Æ·sÃĤW¥«¡AÃĵئb¤¤¬ì¿³«Øªº³J¥Õ½èÃļt¡A¤w¿n·¥½m§L¡A¹wp¦~©³«e±N¥Ó½Ð³ÌÄYÂÔªº¼w°ê©x¤è¬d¼t¡CÃĵØÁ`¸g²zªL°êÄÁªí¥Ü¡A¹ï¦å²G¯e¯f¤zÂZ¯ÀP1101¨ú±o¼Ú¬üÃÄÃÒ¥Rº¡«H¤ß¡C¥Ñ©óP1101¤£¶È¤@½u¥ÎÃÄ¡A¥B¤w¨ú±o¼Ú¬wEMA¤Î¬ü°êFDAªº©t¨àÃÄ»{ÃÒ¡A±N¦U¨É¦³10¦~¡B7¦~¿W½æÅv¡A¥¼¨Ó±N¦³±j«lªº¦¨ªø¤O¹D¡C ¡@¡@¤õ¤O¥þ¶}ªºÃĵءA¥Ø«e¶}µoªº·sÃÄ«~¶µ°ª¹F15Ó¡A¨ä¤¤¡A¦³9¶µ¤w¶i¤J¤HÅéÁ{§É¡A5Ó·sÃĤµ¦~³£¶i¤J¤T´ÁÁ{§É¸ÕÅç¡C ¡@¡@ªL°êÄÁªí¥Ü¡AP1101¬O°ª¯Â«×ªºªø®Ä¤zÂZ¯À¡A²{¦³¾AÀ³¯g¤À§O¬°ºC©Ê¨xª¢¤Î°©Åè³y¦å²ÓM¼W¥Í¯e¯f¡A¥xÆW±M§ðªºB¨x¤w¶i¤J¤T´ÁÁ{§É¡A¦ÓC¨x¤£¶È§¹¦¨¤G´ÁÁ{§É¡A²Ä¤G«¬§ó¶ixÁú°ê¶i¦æÁ{§É¡C<ºK¿ý¤u°Ó> |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2015/3/2 ¤U¤È 01:37:08²Ä 84 ½g¦^À³
|
Dear ¤p^¤j, §Úªº°ÝÃD¬OÃö©ó¦V¬ü°êFDA¥Ó½ÐET¤T´Áªº¶i«× ÁÙ¬O¦]PV¦b¼Ú·ùªº¤T´Á¶i«×delay¥H¦Ü©ó¼vÅTET©ó¬ü°êª½±µ¥Ó½Ð¤T´Áªº¶i«× ·PÁ¤j¤j¸Ñ´b~~~ |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/3/2 ¤U¤È 01:31:58²Ä 83 ½g¦^À³
|
¤½¥q¦³¬ù²¤´£¤F¤@¤U,¤£¹L¶i«×¬O¼Ú·ù¦]¼w°ên¨D¼Ð·Ç¸ûÄY ¥i¯à®t¦³©µ´XÓ¤ë. ½Ðª½±µ°Ý¤½¥qµo¨¥¤H¸û¨Î. |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2015/3/2 ¤U¤È 01:21:31²Ä 82 ½g¦^À³
|
Dear ¤p^¤j, Ãö©ó¤½¥q©ó103¦~10¤ë20¤é¤½§iÃö©ó¦V¬ü°êFDA¥Ó½ÐET¤T´Áªº¶i«×¡A쥻¤½¥q§iª¾103¦~12¤ë©³·|¦³µ²ªG¡AºI¦Ü¥Ø«e§¡µL¥ô¦ó®ø®§¡A¤£¾å±o±z¤§«e¬O§_¦³¸ß°Ý¤½¥q¥H¤F¸Ñ¥Ø«e¶i«×? ¤U¤è¬°ºI¿ý¤½¥q10¤ë20¤é©ó¤½¶}¸ê°TÆ[´ú¯¸¤§«¤j°T®§ (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G ....... (¤T)°£«ez¶i¦æ¤¤Á{§É¸ÕÅç¥~¡A°ò©ó¬Û¦üªº¯e¯fP¯f¾÷¨î¡A¥»¤½¥q©|³W¹º®i¶}P1101¥Î©óªvÀø¦å¤pªO¼W¦h¯g(Essential Thrombocythemia¡A²ºÙET)¤§Á{§É¸ÕÅç¡C½t¦¹¡A¥»¤½¥q©ó10¤ë1¤é»P¬ü°êFDA¶}·|¡A¥»¤½¥q±N¨Ì·ÓFDA©ó10¤ë 13¤é¥¿¦¡¦^ÂФ§«Øij§¹¦¨²Ä¤T´ÁÁ{§É¸ÕÅçpµe®Ñ¡C«Ý¥»¤½¥q¥¿¦¡¦V¬ü°êFDA»¼¥æ²Ä¤T´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A±N¨Ì³W©wµo¥¬«¤j°T®§¤½§i¡C |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2015/3/2 ¤U¤È 01:05:35²Ä 81 ½g¦^À³
|
¤H³£¬O³o¼Ë µ¥¨ìªÑ»ùº¦¨ì4,5¨Õ¤F ¤~·|¤j¤O¬Ý¦n«÷©R°l |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/3/2 ¤U¤È 01:04:51²Ä 80 ½g¦^À³
|
¹L¦~«e¥t¦³°Ý¤½¥q¸ê¥»ÃB°ÝÃD, ¤½¥q¦^µª¤w´£°ª¦Ü40»õ¤¸, ¥i§Ú¬d¸gÀÙ³¡ºô¯¸ÁÙ¬O20»õ1¤d¸U ¦p¤½¥q©Ò¨¥¥¿½T,¨º¦pªG¤½¥q¤µ¦~¿ì²z²{ª÷¼W¸ê ³W¼Ò¥i¯à¤ñ¸û°ª¤]¤ñ¸û¤è«K¤F, |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2015/3/2 ¤U¤È 12:29:32²Ä 79 ½g¦^À³
|
@¤ß«ù¦³,µ¥«ÝÀò§Q ¤§«e§ë¸ê¯«¶©,¤Ó´º...³£¬O¤@¼Ëªº ¦n¤½¥q´N¬O©ê¨c´N¹ï¤F |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/3/2 ¤W¤È 08:17:37²Ä 78 ½g¦^À³
|
ÁÂÁ²q·Q¤j´£¨Ñ¤§Ä_¶Q¸ê®Æ. §ë¸ê¥Í§ÞªÑ¥»¬O°ª·ÀI°ª³ø¹S. ¤£¹L³Ìªñ¥i¯à¦]¤½¥qªÑ»ù¤£¦p¤H·N,¥HPª©±°h¼é ¤£¹L²q·Q¤µ¦~©Î³\·|¦³¤£¿ùªº¶i®i. §Ú¹ï¤½¥q¥ô¦ó¶i«×¦p¦³°ÝÃD,³£·|ª½±µ¥´¹q¸Ü°Ý¤½¥qµo¨¥¤H(§Ú¤]¤£»{ÃÑ)¸ß°Ý,¤½¥q¤]³£·|¸Ô²Ó»¡©ú. ÃĵرN©ó 3¤ë6¤é(¬P´Á¤) PM 3:00 ©óKGI³Í°òÃÒ¨éÁ`³¡¤j¼Ó (¥x¥_¥«©ú¤ô¸ô700¸¹)¡AÁ|¿ìªk¤H»¡©ú·|¡C ¨ì®É©Î³\¦³¤ñ¸û©ú½Tªº®ø®§. ¯¬¦Ï¦~§ë¸ê¶¶§Q. |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2015/3/1 ¤U¤È 06:02:39²Ä 77 ½g¦^À³
|
²q·Q¤j, ÁÂÁ§A´£¨Ñªº¸ê®Æ. ¤Ó¹L±M·~¤F, §Ú¥u¯à¬O±q°]°Èªº¨¤«×¨Ó¬Ý. - §Ú¬O§âÃĵØB/C¨xªº¥«³õ¥ý·í§@0, Y¯uªº¦³¾÷·|,´Nºâ¬O¦hÁȪº. - ¦ý§Ú¹ï¥L¦b©t¨àÃÄPV/ET ªº¼ç¤O´N«Ü¦³´Á«Ý¤F. - ¤×¨ä³Ìªñ¦b»P¤@¦ì§ë¸ê¬ü°ê¥Í§ÞªÑªº°ª¤â²á¹L¤~ª¾¹Dì¨Ó 1. Incyte ³o®a¤½¥q»PPV¦P¬°¦å²G¯e¯fªº¢Û¢Ô¤W¥«3¦~, 2014¦~¦b¬ü°ê´N½æ¤FUS$358m¡AÁÙ¦¬¨ì¼Ú¬w¨ÓªºUS$49m Åv§Qª÷. 2. µM¦Ó®Ú¾Ú§A¥Iªº³sµ²¤º®eÅã¥Ü: MF ¯f¤H¦b¬ü°ê¦ôp¥u¦³¤£¨ì15,000¤H, ¦ÓPV/ET ¯f¤H¦b¬ü°ê¦ôp¦³ ªñ150,000¤Î135,000¤H. Åý§Ú¹ê¦b«ÜÃø¤£¹ïÃĵئ³©Ò´Á«Ý. 3. ¤×¨ä¬OIncyte 2/27¸¹¤½¥q¦¬½L, ¤½¥q¥«Èªñ¬üª÷148»õ¦ÓÃĵإ«È¡]2/26)¥u¦³¬üª÷8»õ. ÁöµMÁÙ«ÝÁ{§É3´Á§¹¦¨¤Î°eÃÄÃÒ¼f¬d. ¨úªºÃÄÃÒ«e,¤]¨S¦³100%ªº¨Æ §Ú¤£¶R¼Ö³z,¦ý¬O³oºØ¸g¹Lpºâ risk/reward ªº§ë¸ê§Ú³Ì·R¤F. ¡]¥H¤W¯ÂÄÝÓ¤H¬ã¨s, ¹ê»Úª¬ªpÁٽФj®a¦h¤F¸Ñ, Y¦³»~´Ó¤£t³d¥ô, ½Ð¤j®a·ÀI¤@©wn©ñ¦b²Ä¤@¦ì¡I¡^ |
|
|
·|û¡G²q·Q10136148 µoªí®É¶¡:2015/3/1 ¤U¤È 12:36:08²Ä 76 ½g¦^À³
|
³o¤@ª©¤H®ðªñ¦ü¥«³õ Åý¤H·Pı¦³®ðµL¤O °£¤F§õÁ`²Î¤j¤´°í«ù©Ò·R¥~ ¤p¬P¬P¤j¤]¤£¦Aµo¨¥Ãö·R ÁÙ¦³ªñ´Áªº¤p^¤j ·Æ½ü8ªÎ¤j µ¹§ÚÌ°T®§ ¹ê¦b·PÁ ¦n¹³¤j®a¹ïªÑ»ùªº¥F¤H·ÓÅU ¦Ó½pÀq ©Î¦³©Ò²¾±¡ ¹L¥h¤p§Ì¹ïÃĵذª¼h¦h©Ò·L¨¥ µL«D¬O·Q½Ð¤½¥q³ê¦^¥«³õªº«H¤ß ªÑ»ù¤U¶^ «ùªÑªÌ³£¤£¦n¨ü ¤p§Ì¤]¤@¼Ë ·Æ½ü8ªÎ¤j ÄÀ¥XÃĵرN©ó3/6ªk»¡ªº®ø®§ ¬Ý¨Ó·Æ½ü8ªÎ¤j ©Î¦³ªk¤HÁÜ½Ð¨ç ©¡®É¥i§_½Ð±z¤À¨É²n¤º®e ¥ý¦æ·PÁ°Õ! Ãĵإثe¤ñ¸û¦³¶i®iªº ¦³ PV , ET , PMF ¥H¤Î B , C¨xµ¥ ³£¬O¥HP1101¬°ªvÀøÃĪ« ¤zÂZ¯À¹ï©óªvÀøPV , ET ©Î¦³¤£¿ùªº®ÄªG ¦ý¹ï PMF ¦ü¥G¦³©Ò¤£¤Î ©Î³\ MPN¬ã¨s°òª÷·|ªººô¯¸ ¥i¥H´£¨Ñ«Ü¦h¸ê°T ¨Ñ§ÚÌ°Ñ¦Ò¾Ç²ß http://www.mpnresearchfoundation.org/Overview-Page ¥t¥~ B , C¨xªº¥«³õ B¨x©ÎÁÙ¦³¨Ç¾÷·|(¦Ü¤Ö¦b¥xÆW¥«³õ) https://tw.news.yahoo.com/b%E8%82%9D%E6%80%8E%E6%B2%BB%E7%99%82-%E5%B9%B2%E6%93%BE%E7%B4%A0%E9%99%8D%E6%8A%97%E5%8E%9F%E5%8A%A9%E6%B2%BB%E7%99%92-020208215.html http://www.tsim.org.tw/journal/jour23-6/01.PDF ¦Ü©óªvÀøC¨x ¦b±j¼ÄÀôµø¤U ¾÷·|©Î³\¤£¤j ¦ý¬O2014¦~ 7¤ë ¤½¥q°ª¼h¦b±µ¨ü¬YÂø»xªº±M³X ³zÅS¤½¥q¤@¨Ç¸gÀç¤è¦V Áö¤]¤£§ï¨ä¹L¥h§@· Åý¤p§Ì¬Ý¤F¤]¥u¯àW¯º ¤£¹L¬Ý±o¥X¨Ó ¤½¥q¦ü¥Gn¥H§C»ùµ¦²¤ ¨Ó¥D¥´¨È¬w¥«³õ ¯à¤£¯à«µ®Ä ¬Ý¥¼¨Óµo®i§a?! http://www.pharmaessentia.com/chinese/images/NEWS/2014073101.pdf ¶È¨Ñ°Ñ¦Ò ½Ð¥Î±zªººÍ´¼§PÂ_ ¨Mµ¦±zªº§ë¸ê ÁÂÁÂ! |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2015/2/27 ¤U¤È 05:36:44²Ä 75 ½g¦^À³
|
Æg!! |
|
|
·|û¡G¦³FUªº¤H10136189 µoªí®É¶¡:2015/2/26 ¤U¤È 08:00:58²Ä 74 ½g¦^À³
|
¬ðµM¶}ªk»¡·|~??? ¦³®ø®§?? |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2015/2/26 ¤U¤È 04:22:02²Ä 73 ½g¦^À³
|
ÃĵرN©ó 3¤ë6¤é(¬P´Á¤) PM 3:00 ©óKGI³Í°òÃÒ¨éÁ`³¡¤j¼Ó (¥x¥_¥«©ú¤ô¸ô700¸¹)¡AÁ|¿ìªk¤H»¡©ú·|¡C Y±z½T©w¥X®u¡A·Ð½Ð¾¨¦¦^ÂЦ^¨ç¡C ¯S§O´£¿ô¡AÃĵج°¿³Âd¤½¥q¦]¦¹ªk»¡·|©ó¿³Âd¦¬½L«áPM 3:00¶}©l ´Á¬ß±zªº»YÁ{«ü±Ð¡IÁÂÁ¡㠦^¨ç½ÐE-mail ¦Ü janice.cheng@kgi.com |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2015/2/26 ¤U¤È 03:24:44²Ä 72 ½g¦^À³
|
ÃĵØÂåÃĪº·s¤@¥Nªø®Ä«¬¤zÂZ¯À P1101 (Peg-P-IFN-alpha-2b¡A¤]ºÙ¬°AOP2014) ¬O´Xªñ³æ¤@ªº(>90%)¤Æ¦Xª«°ª¯Â«×³J¥Õ½è·sÃÄ¡C¬Û¸û¥«³õ¤Wªº¤zÂZ¯À(¦pÀq§JÃļtªºPEG-Intron©Mù¤óÃļtªºPegasys)¯Â«×§ó°ª¡A¨ã¸û§C°Æ§@¥Î¡B¸û°ª¯f¤H¾¯¶q@¨ü«×©M¸û¤Öµ¹ÃĦ¸¼Æªº¯S©Ê¡C§Ú̪º¶ø¦a§Q¦X§@¹Ù¦ñAOP¤½¥q¤w©ó2013¦~¤E¤ë¶}©l¥HP1101ªvÀø¯u©Ê¬õ¦å²y¼W¦h¯g(PV)ªº²Ä¤T´Á¤HÅéÁ{§É¸ÕÅç(NCT01949805)¡A¸ÕÅçµ²ªG¹wp2015¦~¤W¥b¦~µoªí¡C ÃĵØÂåÃÄ©ó2009¦~±Â¤©AOP¤½¥qP1101¦b¼Ú¬wªºµo®iÅv§Q¡A¦ýÃĵØÂåÃĤ´«O¯dP1101©ó¼Ú¬w¥H¥~ªºÅv§Q¡C2012¦~AOP¦b¬ü°ê¦å²G¾Ç¦~·|µoªíPV²Ä¤G´ÁÁ{§É¸ÕÅçµ²ªG¡AªvÀø¤@¦~«á¨ü¸ÕªÌ¹ïªvÀøªº¤ÏÀ³²v¶W¹L90%¡A¥B°Æ§@¥Î»´·L¡CP1101¤wÀòEMA¤ÎFDA¤§PVªº©t¨àÃĸê®æ»{©w¡CÃĵØÂåÃÄ»PFDA¶i¦æ±¹ï±·|ij¤]¬Û·í¦¨¥\¡AFDA¶É¦V¦P·N³z¹L¥H¼Ú¬wªº¤HÅéÁ{§É¸ÕÅçµ²ªGª½±µ¥Ó½Ð¬ü°ê·sÃĤW¥«³\¥i(IND# 119047)¡C2013¦~ÃĵØÂåÃĤ]©ó¥xÆW§¹¦¨«Ø¸m¤@GMP³J¥Õ½è·sÃÄÃļt¡A¥H¥Í²£²Ä¤T´ÁÁ{§É¸ÕÅç¥ÎÃÄ¡AFDA¤ÎEMA¹wp©ó2015¦~(¥Ó½Ð¤W¥«³\¥i«á)¶i¦æÃļt¬dÅç¡C ¯u©Ê¬õ¦å²y¼W¥Í¯g©|µL¦³®ÄªvÀø¤è¦¡¡A©ñ¦å¬°Âå®v³ÌÀu¥ý¨Ï¥Î¥H±±¨î¯gª¬ªºªvÀø¤è¦¡¡CHydroxyurea ©M¤zÂZ¯À¥é³æ¥~¨Ï¥Î¤]¬°ªvÀø¿ï¾Ü¤§¤@¡C¦P¼Ë¥Î©óªvÀø¨u¨£¦å²G¯e¯fªºJakafi¦b2012¦~®ÖãªvÀøìµo©Ê°©ÅèÅÖºû¤Æ«á¡A²Ä¤@¦~¦b¼Ú¬ü¨â¦a´N¦³±µªñ3»õ¬ü¤¸ªº¾P°âÃB¡CJakafi ¥i·í§@P1101¤W¥«®Éªº¾P°âÃB°Ñ¦Ò«ü¼Ð¡CP1101¦b¥Î©óªvÀø¨u¨£¦å²G¯e¯fªº¥«³õ¼ç¤O¬ù¦³10»õ¬ü¤¸¥H¤W¡C |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/2/6 ¤U¤È 04:36:48²Ä 71 ½g¦^À³
|
AOP©t¨àÃĤ½¥q©ó¬ü°ê¦å²G¸~½F¦~·|µoªíP1101¥Î©óªvÀøPV¤§©µªøÁ{§É¸ÕÅç³ø§i 3177 AOP2014 (¤@ºØ·sªº»E¤A¤G¾J¤zÂZ¯À£\)ªvÀø¯u©Ê¬õ¦å²y¼W¦h¯g(PV)±wªÌ¡A¥Ñ¨C¨â¶g¥Ö¤Uª`®gÅÜ´«¦Ü¨C¥|¶g¥Ö¤Uª`®g¡A¥iºû«ùÀø®Ä¨Ã§ï¶iÃĪ«¬r©Ê¤§²Ä I/II´ÁÁ{§É¸ÕÅç I´º ¤£¦P©ó¨ä¥L¤W¥«¤§¤zÂZ¯À¡AAOP2014¬O·s¤@¥Nªºªø®Ä«¬»E¤A¤G¾J¤zÂZ¯À£\-2b¡A¥Dn¥Ñ³æ¤@²§ºcª«²Õ¦¨¡C¥Ñ©ó¤Wz¯S©Ê¡A¹w´Á¦¹ÃĥΩó¯u©Ê¬õ¦å²y¼W¦h¯g(PV)±wªÌ¡A¥i´î¤Öµ¹ÃÄÀW²v¡B´£°ª±wªÌ@¨ü©Ê¡B§ï¶iÂåÅñ¿í±q©Ê¡A¶i¦Ó¦³§ó¦nªºªø´ÁÀø®Ä¡C¦¹ÃĤw¸gEMA©MFDA®Ö¥i¬°©t¨àÃÄ¡A¥Ø«e¥¿³B©ó²ÄIII´ÁÁ{§É¸ÕÅ窺µo®i¶¥¬q¡C ¬ã¨s³]p ì²ÄI/II´Á³æ²Õ¾¯¶q´£¤ÉÁ{§É¸ÕÅçp¦³51¨ÒPV±wªÌ¡A¥]¬A¥¼´¿©Î´¿¸g±µ¨ü²ÓM´î§íÀøªkªÌ¡CAOP2014¤§¥Ö¤Uª`®g¾¯¶q¡A¤À¥¬©ó¨C¨â¶g50²@§J¦Ü¨C¨â¶g540²@§J¡CìÁ{§É¸ÕÅç¥Dn¥Ø¼Ð¬°½T©wAOP2014³Ì¤j@¨ü¾¯¶q¡A¨ÃÆ[¹îªø´Á¦w¥þ©Ê¥H¤Î¦å²G©M¤À¤l«ü¼Ð¥¿±`¤Æ¤§Àø®Ä(µ²ªG¤w©ó2013¦~ASH¦~·|¥Ñ Gisslingerµ¥µoªí)¡Cì¸ÕÅçpµe®Ñ¸g×¥¿«á¡A©óªvÀø¤ÏÀ³¨}¦n¥B°Ñ»P¸ÕÅç¹F¤@¦~¥H¤W¤§¨ü¸ÕªÌ¡A±NAOP2014ª`®g¶g´Á§ó§ï¬°¡u¨C¥|¶g¤@¦¸¡v¡C¥»¸ÕÅ窺³æ¦¸ÃÄ«~¾¯¶q¦bÅܧóª`®g¶g´Á«á¨S¦³§ïÅÜ¡A¦]¦¹±wªÌ¤§AOP2014Á`¼ÉÅS¾¯¶q´î¤Ö¬ù¤@¥b¡CÅܧóª`®g¶g´Á«á¤§¸ÕÅçµ²ªG³ø§i©ó¦¹¡C µ²ªG A´Á¶¡ (¥ÎÃĮɶ¡¤¤¦ì¼Æ34¶g¡A¥§¡¨C¤ë¾¯¶q484 mcg)¡G¨ü¸ÕªÌ°ò©ó¥ý«e²ÄII´ÁÁ{§É¸ÕÅ礧µ¹ÃÄì«h¡A±µ¨ü¨C¨â¶g¤@¦¸¤§ª`®g¶g´Á¡CB´Á¶¡¡A33¨Ò¨ü¸ÕªÌ(¥ÎÃĮɶ¡¤¤¦ì¼Æ12¶g¡A¥§¡¨C¤ë¾¯¶q413 mcg)¡G§¹¦¨²Ä¤@¦~¸ÕÅ礧«á¡A¤´¨C¨â¶gª`®g¡A¨ü¸ÕªÌ¶·Åã¥Ü¨ü¯q©óªvÀø¡Aµû¦ô¨ä¬O§_¾A¦XÅܧóª`®g¶g´Á¡CC´Á¶¡¡A28¨Ò¨ü¸ÕªÌ(¥ÎÃĮɶ¡¤¤¦ì¼Æ42¶g)¡GÅܧóª`®g¶g´Á¦Ü¨C¥|¶gª`®g(¥§¡¨C¤ë¾¯¶q221 mcg)¡C±µ¨üAOP2014ªvÀø¤@¦~«á¡A¦h¼Æ¨ü¸ÕªÌªº¦å²G«ü¼Ð¥i¥¿±`¤Æ¨Ã«O«ùéw¡A©óÅܧóª`®g¶g´Á«á¡A¥ç¥iºû«ù¤@©w¤ô·Ç (¦å²y®e¿n¤ñ¤¤¦ì¼Æ%¡GA´Á¶¡43%¡AB´Á¶¡43%¡AC´Á¶¡42%¡F¥Õ¦å²y¤¤¦ì¼ÆG/l¡GA´Á¶¡6.1¡AB´Á¶¡5.9¡AC´Á¶¡5.7¡F¦å¤pªO¤¤¦ì¼ÆG/l¡GA´Á¶¡246¡AB´Á¶¡211¡AC´Á¶¡204)¡CÅܧóª`®g¶g´Á«á¡A¤j³¡¤À¨ü¸ÕªÌµÊŦªø«×«O«ùéw¦b¥¿±`½d³ò¤º (¥§¡Ècm¡GA´Á¶¡11.4¡AB´Á¶¡8.3¡AC´Á¶¡10.3)¡C¦å²G«ü¼Ð¹F§¹¥þ¤ÏÀ³¨ü¸ÕªÌ¤ñ¨Ò¡GA´Á¶¡42%¡AB´Á¶¡55%¡AC´Á¶¡67 %¡F¦å²G«ü¼Ð¹F³¡¥÷¤ÏÀ³¨ü¸ÕªÌ¤ñ¨Ò¡GA´Á¶¡60%¡AB´Á¶¡71%¡AC´Á¶¡67 %¡C¹F¤À¤l«ü¼Ð¤ÏÀ³¨ü¸ÕªÌ¤ñ¨Ò¡GA´Á¶¡31%¡AB´Á¶¡42%¡AC´Á¶¡75%¡C´î¤Öª`®gÀW²v¤Î¾ãÅéÃĪ«¼ÉÅS¶q¡A¥i¥H´î¤Ö©Ò¦³¤£¨}¨Æ¥ó¥H¤ÎÃÄ«~¬ÛÃö¤£¨}¨Æ¥ó¤§µo¥Í²v(¤£¨}¨Æ¥ó¥§¡¼Æ¤ñ¤W¨C¶g¨C¤H¼ÉÅS¶q)¡GA´Á¶¡0.17/0.09¡AB´Á¶¡0.3/0.09¡AC´Á¶¡0.08/0.03¡C µ²½× ®Ú¾Ú¥»«e¤©ÊÁ{§É¸ÕÅç¹w¥ý©w¸q«ü¼Ð©Ò±o¤§ªì¨B¸ê®ÆÅã¥Ü¡A±µ¨ü¨C¨â¶gª`®gAOP2014¦Ó¤ÏÀ³¨}¦n¤§±wªÌ¡A¶i¤@¨B´î¤Ö¥ÎÃÄÀW²v¦Ü¨C¥|¶gª`®g¤@¦¸¬O¹ê»Ú¥i¦æªº¡C´î¤Öª`®gÀW²v¤£·|¾ÉP¥ÎÃĵL®Ä¡A¤Ï¦Ó¥i©úÅã´£°ª±wªÌ@¨ü©Ê¡C³Ì«á¡AJAK2°ò¦]Åܲ§¶q¥i«ùÄò°§CÅã¥Ü¤zÂZ¯Àªº¼ÉÅS®É¶¡¦Ó«D¤zÂZ¯Àªº¥ÎÃľ¯¶q¡A¬°»¤¾É¤À¤l¤ÏÀ³ªº«n¦]¼Æ¡C¥»½g³ø§i¤§µo²{¡A¾A¥i¤ä«ù¤zÂZ¯À£\¨ã¦³ªvÀøPV¦h«Àø®Ä¤§·§©À¡A¨Ò¦p¸û§C¿@«×¤§AOP2014¡A¨ã¦³ºû«ù»¤µo§K¬ÌºÊ±±¤§«ùÄò®ÄªG¡C ì¤å¥X³B https://ash.confex.com/ash/2014/webprogram/Paper73030.html |
|
|
·|û¡GªL¤p©v10137253 µoªí®É¶¡:2015/2/5 ¤W¤È 09:22:14²Ä 70 ½g¦^À³
|
¥»¤H¤£©ñ°¨«á¬¶,©P¤¹w§i³°ªÑ§Y±N¾ã²z§¹²¦,©P¤@©P¤G¦³¶Rªº,ºâ¬Oªi¬q§CÂIÅo!¦³¶Rªº¦w¤ß©ñ§a~ªø½u³Ì¤Ö¬Ý4000ÂI! |
|
|
·|û¡GªL¤p©v10137253 µoªí®É¶¡:2015/2/4 ¤W¤È 09:28:00²Ä 69 ½g¦^À³
|
¥»¤H1¤ë30¤é¹w§i³°ªÑ,¦pªG2¤ë2¤é¦³¶R¶iªº¤H,À³¸Ó¶R¨ìªi¬q§CÂI!§AÁÙ¦b¬Ý"¨ºÓ¹Ú"¶Ü??¶R³sµ²¤WÃÒªºetf¤~¬O¬Ýªº¨ìªº©Ô! |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/2/2 ¤W¤È 09:31:45²Ä 68 ½g¦^À³
|
·m©t¨àÃÄ°Ó¾÷ ´¼Àº¡BÃĵØÃÄ¥d¦ì 2015¦~02¤ë02¤é 04:10 °OªÌ§ù¿·»T¡þ¥x¥_³ø¾É http://www.chinatimes.com/newspapers/20150202000077-260204 °£¤FÃÄÃÒ˼Æp®Éªº´¼Àº¥~¡AÃĵØÃÄ¥¬§½©t¨àÃÄ»â°ì¥ç¤Q¤À¿n·¥¡A¥Ø«eªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯gªºP1101¡A¤w¶i¤J¼Ú·ù¤T´Á¡A±N¤O©é¦b2016¦~ªì¦P¨B¨ú±o¼Ú·ùEMA©M¬ü°êFDA¤W¥«ÃÄÃÒ¡C ¦¹¥~¡AÃĵؤ]¤Þ¶i¤¤¬ã°|¤À¤l¥Íª«¬ã¨s©Ò°|¤h¨Hõó˱ÂÅv¡u£]¡]beta¡^«¬¦a¤¤®ü«¬³h¦å¯g¡v¤Î¡uÅI¤M«¬¦å²y³h¦å¯g¡vªº·sÃĶ}µo¡A¹wp³Ì§Ö2016¦~¤º¶i¤J¤HÅéÁ{§É¡A·m¶i¥þ²y°ª¹F¼Æ¤Q»õ¬ü¤¸°Ó¾÷¡A¸ÓÃÄÄÝ·s¾÷Â઺·sÃÄ¡AÀÀ¨«©t¨àÃij~®|¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/2/2 ¤W¤È 09:23:43²Ä 67 ½g¦^À³
|
¤u°Ó®É³ø¡G´Nªì¨B²Îp¡A°ê¤ºÃļt¦b©t¨àÃĶ}µo¤w¦³¾ÔªG¡A³Ì¦ªº¬O¤¤¾ó¬ü°ê¤l¤½¥qSynpac¡A¬ãµoªºÃe¨©¤ó¯g¸ÑÃÄ¡uMyozyme¡v¡A±ÂÅv¤©Genzyme¡A¸ÓÃÄ2007¦~¤W¥«¡A¥þ²y1¦~°Ó¾÷¬ù5»õ¬ü¤¸¡]¬ù·s¥x¹ô150»õ¤¸¡^¡ASynpac¨C¦~¬ù¦³3,000¸U¬ü¤¸ªºÅv§Qª÷Ѻª`¡A¤@ª½¨ì2023¦~¡A¤]Åý¤¤¾ó¦~¦~³£¦³¥iÆ[ªº·~¥~¦¬¯q¡C¤µ¦~´¼Àºªº¯ØŦÀù·sÃÄMM398¡A¤µ¦~±N¦V¬ü°êFDA¡B¼Ú·ù©M¨È¬w¥Ó½ÐÃÄÃÒ¡A¹wp´¼Àº¦b¤W¥b¦~§Y¥i±æ¦³¶¥¬q¨½µ{ª÷¦¬¤J¡A©ú¦~°_¦]MM398¥i±æ¦b¼Ú¡B¨È¤W¥«¡A¤]Åý´¼Àº¦]¾P°âÅv§Qª÷¤J±b¡A±N¶}©l±Ò°Ê°ªÀò§Q¡C ¬ã½Õ³BµûªR¡G ®Ú¾Ú²Îp2014¦~¦Ü10¤ë¬°¤î¡A¥þ²y¤W¥«¤§31Ó·s¤À¤lÃĤ¤¡A¨ä¤¤¦³¤»Ó¦b¼Ú¬ü³Q¦C¬°©t¨àÃÄ¡]¯f±w¤H¼Æ¤Ö©ó20¸U¦W¡^¡A¨Ã¹w´Á¥¼¨Ó¼Æ¦~¡A©t¨àÃijQ®Ö㤧³t«×»P¼Æ¶q±N«ùÄò¼W¥[¡A´N¥xÃļt¨Ó¬Ý¡A´¼Àº¤§¯ØŦÀù·sÃÄPEPO2¦b¬üÄÝ©t¨àÃÄ¡A¥ÍµØÁxºÞÀù·sÃÄCX-4945¤]³W¹º¥Ó½Ð©t¨àÃĸê®æ¡A¥HPEPO2¨Ó»¡¡A°£¦b¯ØŦÀù¤W¦X¨Ö¨Ï¥Î5-FU®ÄªG¨Î¡A¹w´Á¥i¬°´¼Àº±a¨ÓÂ׫p¤§Åv§Qª÷¦¬¤J¥~¡Aªñ´ÁMACK°w¹ïPEPO2·s¾AÀ³¯g¤j¸zª½¸zÀù¤]µo¥¬¦w¥þ©Ê»P¦³®Ä©Ê¤§¼Æ¾Ú¡A¬ã½Õ³B»{¬°¦¹±N¦³§UPEPO2«áÄòµo®i»P¾ãÅé»ùȤ§´£¤É¡A¬Gºû«ù´¼Àº¡]4162¡^¶R¶i«Øij¡A¥Ø¼Ð»ù340¤¸¡]PER=19X2015EPS¡^¡C |
|
|
·|û¡G¤p´²¤á10028616 µoªí®É¶¡:2015/1/30 ¤U¤È 03:11:31²Ä 66 ½g¦^À³
|
¥D¦®¡F¸É¥R¤½§i¥»¤½¥q·sÃÄP1101¥Î©óªvÀø¦´Áìµo©Ê°©ÅèÅÖºû¤Æ (Early Primary Myelofibrosis)¤§¤HÅéÁ{§É¸ÕÅçÀò¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®Öã¶i¦æ 1.¨Æ¹êµo¥Í¤é:104/01/30 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥q·sÃÄP1101©ó¬ü°ê»PÂå¾Ç¤¤¤ß¦X§@¤§¡upµe¥D«ù¤H¥D¾É«¬Á{§É¸ÕÅç¡v (IIT¡GInvestigator Initiated Trial)¡A¤é«epµe¥D«ù¤H¦V¬ü°êFDA´£¥X ¥Î©óªvÀø¦´Áìµo©Ê°©ÅèÅÖºû¤Æ(Early Primary Myelofibrosis)¤§¤HÅéÁ{ §É¸ÕÅç¥Ó½Ð(IND½s¸¹125065)¡A¤wÀòFDA®Öã¶i¦æ¡@ 6.¦]À³±¹¬I:µo¥¬¥»«¤j°T®§ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¬ãµo·sÃÄ¥N¸¹©Î¦WºÙ¡GP1101 (2)¥Î³~¡GP1101«Y·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\2b)¡A²{¥¿ ¶i¦æ¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g¤ÎºC©Ê¨xª¢µ¥¤HÅéÁ{§É¸ÕÅç (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡GP1101¥Î©óªvÀø¦´Áìµo©Ê°©ÅèÅÖºû¤Æ (Early Primary Myelofibrosis)¡A¹wp¶i¦æpµe¥D«ù¤H¥D¾É«¬Á{§É¸ÕÅç (IIT¡GInvestigator Initiated Trial)¡B²Ä¤T´ÁÁ{§É¸ÕÅç(Pivotal Trial)¡B ·sÃĬdÅçµn°O (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G P1101¥Î©óªvÀø¦´Áìµo©Ê°©ÅèÅÖºû¤Æ(Early Primary Myelofibrosis)¤§pµe¥D«ù¤H¥D¾É«¬Á{§É¸ÕÅç¡AÀò¬ü°êFDA®Öã¶i¦æ¡@ (¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î (¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î (¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡G²Ö¿n¤w§ë¤J¸ÓÁ{§É¸ÕÅ礧¶O¥Î¬ù345¤d¤¸ (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G A.¹wp§¹¦¨®É¶¡¡G¹wp©ó2017¦~¤¤§¹¦¨²Ä¤@¶¥¬q13¤H¤§¸ÕÅç B.¹wpÀ³t¾á¤§¸q°È¡G¥»¤½¥q±N¤ä¥I°£¨Ò¦æÂåÀø·ÓÅ@(routine clinical care)¥H¥~¤§Á{§É¸ÕÅç¬ÛÃö¶O¥Î (6)·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë ¸ê±Á{·ÀI¡A§ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/30 ¤U¤È 12:18:47²Ä 65 ½g¦^À³
|
Wu7016¤j¤j¦n¡G (1) ·s¤@¥Nªø®Ä«¬¤zÂZ¯ÀP1101¥Î©óªvÀø¦å¤pªO¼W¥Í¯g(ET)ªº·sÃĥثe¥¿¿n·¥·Ç³Æ²Ä¤T´Á¶}©ñ©ÊÁ{§É¹êÅçp¹º®Ñ¡C (2) Ãö©ó¤½¥q¤µ¤é¤½§i¤§®ÖãP1101¦b¬ü°ê¶i¦æ PMF(Primary Myelofibrosis)ìµo©Ê°©ÅèÅÖºû¤Æªº¤HÅé¸ÕÅçµ²ªGY¼Æ¾Ú¨}¦nªº¸Ü¡APMF±N¦³¾÷·|¹³ET¦]PV¤HÅé¹êÅç¼Æ¾Ú¦Ó¥[³t¤HÅé¹êÅ窺¶i«×¡C ¥H¤W´£¨Ñµ¹¦U¦ì¤j¤j°Ñ¦Ò¡A¨Ã§Æ±æ¦U¦ì¤j¤j¤]´£¨Ñ¬ÛÃö°T®§¡AÁÂÁ¡I |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2015/1/30 ¤W¤È 11:37:15²Ä 64 ½g¦^À³
|
À³¬OPhase 2§a¡I¨Ì·Ó¤½¥q¤W¶Çªº¸ê®Æ°T®§¨Ó¬Ý. |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2015/1/30 ¤W¤È 11:05:14²Ä 63 ½g¦^À³
|
¦A½Ð°Ý¦U¦ì¤j¤j,Ãö©ó¤½¥q¤µ¤é¤½§i¤§®ÖãP1101¦b¬ü°ê¶i¦æ PMF(Primary Myelofibrosis)ìµo©Ê°©ÅèÅÖºû¤Æªº¤HÅé¸ÕÅç¡C ¬O¥NªíPMF¥i¥H¦b¬ü°ê¶}©l¶i¦æPhase 1ªº¤HÅé¹êÅç¶Ü? ¦p¬Oªº¸Ü¡APMF¦³¾÷·|¹³ET¦]PV¦]¦¹¥i¥H¥[³t¤HÅé¹êÅ窺¶i«×¶Ü? ·PÁ¦U¦ì¤j¤jªº¨ó§U¸Ñ´b!!!! |
|
|
·|û¡Gwu701610136601 µoªí®É¶¡:2015/1/30 ¤W¤È 10:55:03²Ä 62 ½g¦^À³
|
Dear all, ½Ð°Ý¦U¦ì¤j¤jª¾¹DÃö©ó¤½¥q©ó103¦~10¤ë20¤é¤½§iÃö©ó¦V¬ü°êFDA¥Ó½ÐET¤T´Áªº¶i«×¶Ü?(쥻¤½¥q§iª¾103¦~12¤ë©³·|¦³µ²ªG) (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G (¤@)P1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅ秹¦¨«á¡A±N¦V¼Ú¬wEMA»¼ ¥æ·sÃĬdÅçµn°O¥Ó½Ð¡AÃÄÃÒ±N¬°AOP¤½¥q©Ò¾Ö¦³¡C¦P®É¥»¤½¥q¤wÀò¬ü°êFDA ¦P·N¡A¥iª½±µ¥Ó½Ð·sÃĬdÅçµn°O¥Ó½Ð¡AÃÄÃÒ±N¬°¥»¤½¥q©Ò¾Ö¦³¡C (¤G)P1101¥Î©óªvÀøºC©ÊC«¬¨xª¢°ò¦]«¬²Ä2«¬¤§Á{§É¸ÕÅç¡A¥»¤½¥q¤é«e¤w¦V¥xÆW ÂåÃÄ«~¬dÅ礤¤ß(CDE)¿Ô¸ß²Ä¤T´ÁÁ{§É¸ÕÅçpµe®Ñ³]p¡A±N¾Ú¥H³W¹º²Ä¤T´Á Á{§É¸ÕÅç¡C (¤T)°£«ez¶i¦æ¤¤Á{§É¸ÕÅç¥~¡A°ò©ó¬Û¦üªº¯e¯fP¯f¾÷¨î¡A¥»¤½¥q©|³W¹º®i¶} P1101¥Î©óªvÀø¦å¤pªO¼W¦h¯g(Essential Thrombocythemia¡A²ºÙET)¤§Á{ §É¸ÕÅç¡C½t¦¹¡A¥»¤½¥q©ó10¤ë1¤é»P¬ü°êFDA¶}·|¡A¥»¤½¥q±N¨Ì·ÓFDA©ó10¤ë 13¤é¥¿¦¡¦^ÂФ§«Øij§¹¦¨²Ä¤T´ÁÁ{§É¸ÕÅçpµe®Ñ¡C«Ý¥»¤½¥q¥¿¦¡¦V¬ü°êFDA »¼¥æ²Ä¤T´ÁÁ{§É¸ÕÅç¥Ó½Ð¡A±N¨Ì³W©wµo¥¬«¤j°T®§¤½§i¡C |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/30 ¤W¤È 10:33:27²Ä 61 ½g¦^À³
|
¤½§i¥»¤½¥qÀò¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®ÖãP1101¦b¬ü°ê¶i¦æ PMF(Primary Myelofibrosis)ìµo©Ê°©ÅèÅÖºû¤Æªº¤HÅé¸ÕÅç 1.¨Æ¹êµo¥Í¤é:104/01/29 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ:¤½§i¥»¤½¥qÀò¬ü°ê¹«~ÃĪ«ºÞ²z§½(FDA)®ÖãP1101¦b¬ü°ê¶i¦æ¡@ PMF(Primary Myelofibrosis)ìµo©Ê°©ÅèÅÖºû¤Æªº¤HÅé¸ÕÅç¡A¤wÀò¬ü°êFDA ¨ü²z¡A¨Ãµ¹¤©IND½s¸¹125065 6.¦]À³±¹¬I:¤½§i°T®§©ó¤½¶}¸ê°TÆ[´ú¯¸ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:µL |
|
|
·|û¡GªL¤p©v10137253 µoªí®É¶¡:2015/1/30 ¤W¤È 09:39:14²Ä 60 ½g¦^À³
|
¶R°ò´Á°ªªº¥xªÑ,¤£¦p¶R¤WÃÒetf¦p¤¸¤WÃÒ,³°ªÑ¾ã²z§¹«á,¼Q¥X! |
|
|
·|û¡GªL¤p©v10137253 µoªí®É¶¡:2015/1/28 ¤W¤È 10:45:41²Ä 59 ½g¦^À³
|
122¯}¤F...¤U¨Ó¬Ý?Àq«s.... |
|
|
·|û¡GªL¤p©v10137253 µoªí®É¶¡:2015/1/26 ¤U¤È 03:27:52²Ä 58 ½g¦^À³
|
122§Ö¯}¤F¼Ú... |
|
|
·|û¡GAlan10136952 µoªí®É¶¡:2015/1/24 ¤W¤È 11:51:26²Ä 57 ½g¦^À³
|
°ê²£C¨x¤zÂZ¯À ¥i±æ2¦~¤º°Ý¥@¡mÁp¦X³ø¡n ¡iÁp¦X³ø¡þ°OªÌ³¯«BøÊ¡þ°ª¶¯³ø¾É¡j ¡@¡@½Ã¥ÍºÖ§Q³¡±À®i¡u·sÃÄÁ{§É¸ÕÅçpµe¡v¡A¬Qµoªí¦~«×¦¨ªG¡A°ª¶¯ÂåÃĤj¾Çªþ³]Âå°|Àò±o°ß¤@ªº¯SÀu¡A¥Ø«e·Ç³Æ¶i¤J²Ä¤T¶¥¬q¤HÅé¸ÕÅ窺°ê²£C¨x¤zÂZ¯À¡A¤]¦b°ªÂ媺Á{§É¸ÕÅ礤¤ß¸ÕÅç¡A¹wp¨â¦~¤º§¹¦¨¡A©¡®É±N¦¨¬°¥þ¥x²Ä¤@Ó¥»¤g¬ãµoªºC¨xªvÀø¥ÎÃÄ¡C ¡@¡@°ªÂå¤jªþ³]Âå°|Á{§É¸ÕÅ礤¤ß¥D¥ô½²¤å®iªí¥Ü¡A¸Ó°|¥Ø«e¥¿¶i¦æ¥|ºØ·sÃĪºÁ{§É¸ÕÅç¡A¨ä¤¤¤@´ÚC¨xªºª`®g¤zÂZ¯À¡A¤w§¹¦¨²Ä¤G´ÁªºÁ{§É¸ÕÅç¡A§Y±N¶i¤J²Ä¤T¶¥¬qªº¸ÕÅç¡C ¡@¡@½²¤å®iªí¥Ü¡A°ê¤ºÃļt¹L¥h´¿¦h¦¸¹Á¸Õ¬ãµoC¨x¤zÂZ¯À¡A¦ý±q¥¼¦¨¥\¹L¡A³o¦¸ªº¸ÕÅçY¬O¦¨¥\¡A±N¦¨¬°¥þ¥xÆW²Ä¤@Ó¥»¤g¬ãµoªºªvÀøC¨x¤zÂZ¯À¡C°ªÂå¤jªþ³]Âå°|°Æ°|ªø§E©ú¶©ªí¥Ü¡A¤@¯ë¤zÂZ¯À©ö¤Þµoµo¿N¡BÀYµh¡B¦å²y°§Cµ¥°Æ§@¥Î¡A¦Ó³o´Ú·sÃÄ«hݨã¦w¥þ©Ê¤ÎÀø®Ä¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/1/23 ¤U¤È 02:52:20²Ä 56 ½g¦^À³
|
@¤ßµ¥,ºCºCµ¥.®ø®§§Y±N³°Äò¤½¥¬. 1.¸gÀÙ³¡¤u·~°Ï¬ì§Þ¨Æ·~®Öã¨ç±N©µ¦Ü3¤ë. 2.IPO¥i¯à©µ¦ÜQ3 3.¤µ¦~ªÑªF·|±N©ó5¤ë¥÷Á|¦æ. 4.°ò¥»±¤£ÅÜ,¤T´ÁÁ{§É¼Æ¾Ú¨}¦n,PV¦¬®×±N©ó3¤ë§¹¦¨. ÂÔ®¥°Ñ¦Ò. |
|
|
·|û¡GªL¤p©v10137253 µoªí®É¶¡:2015/1/21 ¤U¤È 12:47:17²Ä 55 ½g¦^À³
|
§ÚªB¤Í·íªì¥H¬ù20¶ô¶R¶i,220¥H¤W¥þ¥X²æ,¤@°ï¤H¶i¦b15-20,¶R¦b200¥H¤W§Ú¬Ý¬O«ÜÃø¸Ñ®M¤F |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2015/1/21 ¤W¤È 11:35:53²Ä 54 ½g¦^À³
|
¥Í§Þ²£·~¡G2015¥Í§ÞÃþªÑ±N¥H¦³¹ê½è°^ÄmªÌ¬°Ä¹®a ƒÞ2015¦~¦b²£·~¥¿¦Vµo®iÁͶդ´¦b¤U¡A¥Í§ÞÃþªÑÀ³¥i¦^´_¤Wº¦®æ§½¡G2014¦~¥xÆW¥Í§ÞªÑ¾ú¸g¤C¤ë°ò¨È´Á¤¤¤ÀªRµ²ªG¤£¦p¹w´Á¡A¥«³õ¥¢±æ½æÀ£´é²{¤U¡A§ë¸ê®ðª^±Y¼ì¡AP¨Ï¤W¥«Âd¥Í§Þ«ü¼Æ¾D³{¤j´T«××¥¿¡A»P³s°Ê©Ê°ª¤§NBI«ü¼Æ¤ñ¸û¡A¨âªÌ¤w¨ÄÂ÷¡A¥Ñ©óÆ[¬Ý¬ü°êNBI«ü¼Æ¨«¶Õ¤´Ã°·¦V¤W¡AÅã¥Ü¾ãÅé²£·~ÁͶÕÀ³ÁÙ¬O§e¥¿¦Vµo®i¡A¬G¹w´Á¥xÆW¥Í§ÞÃþªÑ¦b¾ú¸g2014¦~ªº¬~§«á¡A2015¦~¦b²£·~¤´ºû«ù¥¿¦Vµo®iÁͶդU¡AÀ³¥i¦^´_¤Wº¦®æ§½¡A¦ý¦b¨«¶Õ¤W¡A¹w´Á¤£¦A¹³¹L©¹¸sº¦¸s¶^¡A¦Ó·|´ÂÃÄ«~«¶Õ¡BÂå§÷«½è¡AÀuªÌ³Ó¥X¤§§ë¸êª^³ò¡C ÂåÃÄ«¶Õ¡BÂå§÷«½è¬°¥x¥Í§ÞªÑ2015¦~§ë¸ê«ÂI¡G¥Ñ©ó¥xÆWÂåÃÄÃþªÑ¤×¨ä¬O·sÃıڸs¡A¦]¦h³BÁ{§É¬ãµo¶¥¬q¡AP¨Ïµu´ÁÃø¬Ý¨ì¹ê½èÀò§Q°^Äm¡A¥[¥H¨ü°ò¨È¨Æ¥ó¼vÅT¡A§ë¸êªÌ¹ï·sÃĤ½¥q¤§À˵ø§ó¥[ÄYV¡AP¨Ï¥¼¨ÓÃø¨£¸sº¦¸s¶^¤§¨«¶Õ. |
|
|
·|û¡G±æ¤Ñ10133199 µoªí®É¶¡:2015/1/20 ¤U¤È 11:30:46²Ä 53 ½g¦^À³
|
¦]µØ«ç»ò¬Ý³£¤ñ¸û¦n |
|
|
·|û¡GAlan10136952 µoªí®É¶¡:2015/1/20 ¤U¤È 04:03:53²Ä 52 ½g¦^À³
|
¤º¦æ¤H¬Ýªù¹D¡A¥~¦æ¤H¬Ý¼ö¾x ¦³ÂI¶¢¿ú´N¥[´î¦h¶i¨Ç§a¡I |
|
|
·|û¡G±¶10137165 µoªí®É¶¡:2015/1/20 ¤U¤È 02:24:49²Ä 51 ½g¦^À³
|
Âû¼LÅÜÀn¼L¡IÀn³¶µLÁn¡AªÑ¤ýÅܦa¤ý¡Aµ¥ªÑ»ù¤Wº¦¤~·|¦³°¨«á¯¥ªº¥ýª¾¥X¨Ó¡AºG¡I¦¹®ÉµLÁn³Ó¦³Án¡C |
|
|
·|û¡GªL¤p©v10137253 µoªí®É¶¡:2015/1/20 ¤U¤È 01:42:03²Ä 50 ½g¦^À³
|
»¡¦nªºªÑ¤ý£z?122¦A¶^¯}ªº¸Ü...¥h¦~´N¦³»¡¤F¼Ú |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/14 ¤W¤È 10:35:57²Ä 49 ½g¦^À³
|
¦U¦ì¤j¤j¦n¡G ¥Ø«eP1101 ªvÀøB«¬¨xª¢©MC«¬¨xª¢¦b¤HÅéÁ{§É¸ÕÅç¬O¨C2©Pª`®g¤@¦¸¡C ¾ãÓÀøµ{¶·¬I¥´24°w¡C ¸ò¦U¦ì¤j¤j¤À¨É¥»¤H½²©mªB¤Í¦b¸g¹L9¦¸ª`®g«áªº©â¦åÀËÅç¡A ¦å²G¤¤ªº¯f¬r¤ÏÀ³¤w§e³±©Ê¡A¤]´N¬O¤wµL¯f¬r¤ÏÀ³¡A¥Ø«e¤´«ùÄò°lÂÜ¡C ¥t¤@¦ìÁ©mªB¤Í¡A¦bªvÀø«e©â¦åÀËÅç¯f¬r¼Æ¡A¼Æ¶q°ª¹F180¦h¸U¡A ¬I¥´²Ä1°w«á©â¦åÀËÅç¡A¯f¬r«ü¼Æ°¦Ü1¸U¦h¡A ¬I¥´²Ä2°w«á©â¦åÀËÅç¡A¯f¬r«ü¼Æ¦A°¨ì4¤d¦h¡A ¬I¥´²Ä3°w«á©â¦åÀËÅç¡A¤wµL¯f¬r¤ÏÀ³¡A ¬Q¤é¤w¬I¥´²Ä4°w¡C ¦b¦¹¦A¦¸©IÆ~¨ÃäY¦³ªB¤Í¬°B¨x¡BC¨x©ÒW¡AÀ³ºÉ¦±µ¨üªvÀø¡C |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/7 ¤W¤È 11:30:55²Ä 48 ½g¦^À³
|
³¯«º¦Ð¤j§A¦n: §Ú³Ì°ª¦³¶R¨ì250¤¸ |
|
|
·|û¡G³¯«º¦Ð10138828 µoªí®É¶¡:2015/1/7 ¤W¤È 11:16:54²Ä 47 ½g¦^À³
|
ª÷¨©¨©¤j §Aªº¦¨¥»¤£´N¥u¦³10¦h¶ô «z |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/7 ¤W¤È 10:36:49²Ä 46 ½g¦^À³
|
CC¤j¦n¡G P1101 PV ¯u©Ê¬õ¦å²y¼W¥Í¯g3´Á¤HÅé¹êÅç¹wp©óQ1¦¬®×§¹¦¨¡C ©Ò¥H¤½¥q¥Ø«e¨Ã¤£·|¤½§i¡Anµ¥¨ì¦¬®×§¹¦¨¤~·|¤½§i¡C ·sÃħë¸ê¬Oªø´Á»ùȧë¸ê¡A¸ÛÀµ«Øij¤£n¤Ó¦b¥Gµu´Áº¦¶^¡C ¥»¤H¬O±q¥Á°ê97¦~§ë¸ê«ùªÑ¦Ü¤µ¡A¥BY¦³¶¢¸m¸êª÷®É´NÄ~Äò§ë¤J¡A §ë¸ê¤H§ë¸ê·sÃIJ£·~°È¥²ÄY®æ±±ºÞ·ÀI¡A¤Á¤Å°ªºb±ì§ë¤J¡C |
|
|
·|û¡GCC10139226 µoªí®É¶¡:2015/1/7 ¤W¤È 09:29:30²Ä 45 ½g¦^À³
|
ª÷¤j±z¦n,´£¤ÎP1101 PV ¯u©Ê¬õ¦å²y¼W¥Í¯g3´Á¤HÅé¹êÅ禬®×§¹¦¨¡C ½Ð°Ý:®ø®§ªº¨Ó·½¬O¦ó³B?¤½¥q¥Ø«e³£¨S¦³¥ô¦ó¤½§i,¤]§ä¤£¨ì¬ÛÃö°T®§,©Ò¥H·Q¸ò±z½T»{¤@¤U,·Ó²z,¤½¥qÀ³¸Ón¤½§i§a?¦]¬°¬O¥H¦n®ø®§¨Ó¸ÑŪ§a?«ç»ò³£¨S¤ÏÀ³? ¦]¬°±zªø´ÁÃöª`ÃĵØ,¹ï¤½¥q¤]¤ñ¸ûÁA¸Ñ,¥i§_¦A¬°§Ṳ́À¨É¤@¤U,«D±`·PÁ |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/6 ¤W¤È 10:56:29²Ä 44 ½g¦^À³
|
¦U¦ì¤j¤j¦n¡G ÃĵØ104¦~«n¦æ¨Æ¾ä¡G 1. ¨ú±o¤u·~§½«¤j¬ì§Þ¨Æ·~®Öã¨ç¡C 2. P1101 PV ¯u©Ê¬õ¦å²y¼W¥Í¯g3´Á¤HÅé¹êÅ禬®×§¹¦¨¡C 3. °e¥ó¥Ó½Ð¤WÂd¡C 4. ET ¦å¤pªO¼W¥Í¯g¡A¬ü°ê¥xÆWÁ{§É¶i¤J²Ä3´Á¡C 5. B¨x¶i¤J²Ä2´Á¡þ3´ÁÁ{§É¹êÅç¡CC¨x¶i¤J²Ä3´ÁÁ{§É¹êÅç¡C 6. OraxolªvÀø¨ÅÀù¤fªAµµ§ü¾J²Ä3´ÁÁ{§É¹êÅç¡C 7. P1101 ªvÀøPV ¯u©Ê¬õ¦å²y¼W¥Í¯g¡A¼Ú·ùEMA¡B¬ü°êFDA¦P¨B¥Ó½ÐÃÄÃÒ¡C |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/5 ¤U¤È 02:34:25²Ä 43 ½g¦^À³
|
¤Óºò±i¤j¤j¦n¡G ÃĵØP1101¤zÂZ¯ÀªºÀuÂI´N¬O°Æ§@¥Î«Ü¤p¤S§óªø®Ä¡A ¬I¥´ªÌ¥u»Ý¨C2©Pª`®g¤@¦¸¡A°Æ§@¥Î¤j´T´î¤Ö¡A °£¦¹¤§¥~ÁÙ¥i¥H§ïµ½¦]¨x¯f¬r¤Þµoªº¯h¡A²{¦bºë¯«®ð¦â³£¤ñªvÀø«e¦n«Ü¦h¡C «áÄò°lÂÜ·|¦A¸ò¦U¦ì¤j¤j³ø§i»P¤À¨É¡C |
|
|
·|û¡G¤Óºò±i10135421 µoªí®É¶¡:2015/1/5 ¤U¤È 01:58:57²Ä 42 ½g¦^À³
|
«D±`·PÁª÷¨©¨©´£¨Ñ«n°T®§. ¤zÂZ¯À³Ì¤jªº¸á¯f´N¬O°Æ§@¥Î ,Ãö«Y¨ì¥«³õ±µ¨ü«× . ¥i¥H¸ß°Ý¤@¤U±zªB¤Í°Æ§@¥Î¤ÏÀ³ªº±¡ªp¸òµ{«×¦p¦ó(Ãþ·P«_¯gª¬¡B¸zG¡BºÎ¯v µ¥) ? ¼vÅT¤Ñ¼Æ ? ·|¼vÅT¨ì¤u§@¸ò¥Í¬¡¶Ü ? ¨®Ç¤]¦³¨Ç±aìªÌ,¦]¤§«e¤zÂZ¯À°Æ§@¥Î¤Ó¤j¦Ó¼È½wªvÀø . °Æ§@¥Î : ù¤óÃļt(ªø®Ä)¡GPegasys(Peginterferon alfa-2a)135 mcg/ml ù¤óÃļt(ªø®Ä)¡GPegasys(Peginterferon alfa-2a)180 mcg/ml¡C ¥ýÆF¸¶¶®(ªø®Ä)¡GPeg-Intron(Peginterferon alfa-2b)80³æ¦ì(1.5mcg/kg)¡C ¥ýÆF¸¶¶®(ªø®Ä)¡GPeg-Intron(Peginterferon alfa-2b)100³æ¦ì(1.5mcg/kg) °Æ§@¥Î¡G³q±`°Æ§@¥Î·|¦bªvÀø«á¨â¶gº¥º¥®ø¥¢ 1.Ãþ·P«_¯gª¬¡G¬È´H¡Bµo¿N¡B¯h¡B¦Ù¦×»Äµh¡BÀYµhµ¥¡K 2.¸zG¤£¾A¡G¹¼¤¤£®¶¡Bäú¤ß¡B¹Ã¦R¡B¸¡Âm¡B¨ýı§ïÅÜ¡B¤fµÄ©Î³ïÄV°®Àê¡C 3.¥Ö½§°®Àê¡BµoÄo¡BÅé«´î»´¤ÎªvÀø¥½´Á¼È®É©Ê±¼¾v¡C 4.¥Õ¦å²y©Î¦å¤pªO¤U°¡C 5.ºÎ¯v»Ùê¡Bºë¯«ºò±i¡B©Î¨Ï¬J¦³ªº¤ßŦ¯e¯f¦p°ª¦åÀ£¡B¯Ýµh¡B¤ß±ªµ¥¯gª¬´c¤Æ¡C 6.»Ý©w´Á°lÂܦå²G¬ÛÃöÀËÅç 7.¨Ï¥Îªì´Á¬°´î¤Ö°Æ§@¥Î¥i©óªvÀø«e30¤ÀÄÁµ¹¤©¦ppanamaxÃþªº¸Ñ¼öÂíµh¾¯¡C |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/5 ¤W¤È 11:25:54²Ä 41 ½g¦^À³
|
¦U¦ì¤j¤j¦n¡G ¥Ø«eP1101 ªvÀøB«¬¨xª¢©MC«¬¨xª¢¦b¤HÅéÁ{§É¸ÕÅç¬O¨C2©Pª`®g¤@¦¸¡C ¸ò¦U¦ì¤j¤j¤À¨É¥»¤H½²©mªB¤Í¦b¸g¹L9¦¸ª`®g«áªº©â¦åÀËÅç¡A ¦å²G¤¤ªº¯f¬r¤ÏÀ³¤w§e³±©Ê¡A¤]´N¬O¤wµL¯f¬r¤ÏÀ³¡A¦ý¤´»Ý°µ°lÂÜ¡C ¥t¤@¦ìÁ©mªB¤Í¡A¦bªvÀø«e©â¦åÀËÅç¯f¬r¼Æ¡A¼Æ¶q°ª¹F180¦h¸U¡A ¬I¥´²Ä¤@°w«á©â¦åÀËÅç¡A¯f¬r«ü¼Æ°¦Ü1¸U¦h¡A ¬I¥´²Ä¤G°w«á©â¦åÀËÅç¡A¯f¬r«ü¼Æ¦A°¨ì4¤d¦h¡A ²{¦b¤w¸g¥´¤F²Ä¤T°w¡A¬I¥´¹Lµ{¶¶§Q¥B°Æ§@¥Î«Ü¤p¡A ¥Ø«e¤´Ä~ÄòªvÀø¤¤¡C |
|
|
·|û¡GOOXX10022393 µoªí®É¶¡:2015/1/5 ¤W¤È 11:17:00²Ä 40 ½g¦^À³
|
ª÷¤j¤j,ÁÂÁ±zªº°T®§, §Æ±æ¤j®a³£¯à±o¨ì§´µ½ªvÀø. |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2015/1/5 ¤W¤È 10:50:05²Ä 39 ½g¦^À³
|
OOXX¤j¤j¦n¡G ¥Ø«eP1101 ªvÀøB«¬¨xª¢©MC«¬¨xª¢¦b¤HÅéÁ{§É¸ÕÅ綥¬q¡A ©ó¥þ¥x16©Ò±Ð¾ÇÂå°|¶i¦æ¡A ¥Ñ³¯©w«H°|¤h¡B¹ù¹B½d°|¤h¡B³¯°öõ°|¤h»P²ø¸UÀs±Ð±Âµ¥ªñ50¦WÂå¥Í¦@¦P°Ñ»P¡C 16©Ò±Ð¾ÇÂå°|¦W³æ¡G ¥x¤jÂå°| ¥x¤jÂå°|¶³ªL¤À°| ¤¤°êÂå¾Ç¤j¾Çªþ³]¾Ç°| ¥x¥_ºa¥ÁÁ`Âå°| ¥x¤¤ºa¥ÁÁ`Âå°| ¦ò±Ð·OÀÙºî¦XÂå°|¥x¥_¤À°| ¨ÈªF¬ö©ÀÂå°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|°ò¶©¤À°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|¥x¥_¤À°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|ªL¤fÁ`°| °]¹Îªk¤Hªø©°¬ö©ÀÂå°|°ª¶¯¤À°| °ª¶¯Âå¾Ç¤j¾Çªþ³]¤¤©M¬ö©ÀÂå°| °ê®õºî¦XÂå°| ¹ü¤Æ°ò·þ±ÐÂå°| ¸q¤jÂå°| ©_¬üÂå°| |
|
|
·|û¡G¤Óºò±i10135421 µoªí®É¶¡:2015/1/1 ¤W¤È 10:21:41²Ä 38 ½g¦^À³
|
B¨x«çªvÀø¡H¤zÂZ¯À°§Üì§Uªv¡ µØ¤H°·±dºô§@ªÌ¡G µØ¤H°·±dºô °OªÌ¬x·¶µX¡þ¥x¥_³ø¾É | µØ¤H°·±dºô ¡V 2014¦~9¤ë27¤é ¤W¤È10:02 ¡K B¨xªvÀø¤À¨âÃþ¡@¤fªA¡B°w¾¯¤j¤£¦P ¬°ÁקK¤Wzª¬ªpªºµo¥Í¡A´^¦¨¤¸Âå®v±j½Õ¡A´M¨D±M·~ªvÀø«D±`«n¡C¦Ó¥Ø«eB«¬¨xª¢ªºªvÀø¡A¨Ì¾Ú¨Ï¥Î¤è¦¡¤£¦P¡A¥i¤À¬°¤fªA§Ü¯f¬rÃĪ«¡Bªø®Ä«¬¤zÂZ¯À¨âºØ¿ï¾Ü¡C¤£¹L¡A¤@¼Ë¬OB¨xªvÀø¡A³o¨âªÌ¶¡¨s³º¦³¦ó®t²§©O¡H ´^¦¨¤¸Âå®v¶i¤@¨B¸ÑÄÀ¡A¤fªA§Ü¯f¬rÃĪ«¡A¥Dn¬OÂǥѧí¨îB¨x¯f¬r½Æ»s酶¡AªýÂ_¯f¬rDNA¦X¦¨¡A¤]´N¬OÂǥѰ§CB¨x¯f¬r½Æ»s¡A¨Ó¹F¨ì¯f±¡ªº±±¨î¡C ¦Óªø®Ä«¬¤zÂZ¯À°£¤F¦³§í¨î¯f¬r½Æ»sªº®ÄªG¥~¡AÁÙ¦³½Õ¸`§K¬Ì¨t²Î¡B¬¡¤Æ§K¬Ì²ÓM¡A²M°£¨ü¯f¬r·P¬V¤§¨x²ÓM¡A¸g¥Ñ«ùÄò§K¬Ì½Õ±±¡A¦³§U©ó°§C¬Æ¦Ü©ó²M°£B«¬¨xª¢ªí±§Üì¡C§Y¨Ï±wªÌ°±ÃÄ«á¡A¦¹¹D§K¬Ì«Ì»Ù¤]¯àÄ~Äò§@¥Î¡C ªø®Ä«¬¤zÂZ¯ÀÀøµ{µu¡@°±ÃÄ«áµL°Æ§@¥Î ¤£¹L¡A¹ï©óB«¬¨xª¢±wªÌ¦Ó¨¥¡A¦b¤fªA§Ü¯f¬rÃĪ«¡Bªø®Ä«¬¤zÂZ¯À¨âªÌ¶¡¤S¸Ó¦p¦ó¿ï¾Ü¤~¬¢·í¡A¥B²Å¦XÓ¤H»Ý¨D©O¡H´^¦¨¤¸Âå®v«ü¥X¡A¨Æ¹ê¤W¡A¨âºØÃĪ«¬Ò¦³¤£¿ùªºÀø®Ä¡A¦ý¬O¦bÀøµ{ªøµu»P¥ÎÃĤè«K©Ê¡B§ÜÃĩʤW¦³¬Û·íªº®t²§©Ê¡C ¥H¥ÎÃĤè«K©Ê¨Ó»¡¡A¤fªAÃĪ«´N¤ñ¤zÂZ¯À°ª¥X³\¦h¡A¤£¶È¤£»Ý©Ó¨ü®Á°w¤§µh¡A¨C¤ÑªA¥Î1ÁûÃĪ«¡A´N¯à»´©ö§¹¦¨¡C¦ý¤fªAÃĪ«¤@¯ë¦Ó¨¥»Ýªø´ÁªA¥Î¡A¥i¯à¨Ì±wªÌ¹ïÃĪ«Àø®Ä¤§®t²§¡A©Ò»ÝªºÀøµ{®É¶¡¤]¦³©Ò¤£¦P¡C ³æ´N°ê¤º°·«Oµ¹¥I¨î¨C¤H2¦¸Àøµ{¡B¤@¦¸Àøµ{3¦~ªº³W©w¨Ó¬Ý¡AYµ¹¥I¦~µ²§ô¡A±wªÌ¥i¯à»Ý±Á{¯f±¡©|¥¼²¬Â¡¡A«o»Ý¦Û¦æt¾áÃĪ«¶O¥Îªºµ~¹Ò¡A¥B¤fªAÃĪ«¸û®e©ö¦³°±ÃÄ«á´_µoªº°ÝÃD¡C§ÜÃĩʦb²Ä¤@¥Nªº¤fªAÃĪ«¬O±`¨£ªº²{¶H¡A¨Ã¥B³y¦¨³\¦hÁ{§É°ÝÃD¡A¤£¹L¥Ø«e¼sªx¨Ï¥Îªº·s¤@¥N¤fªAÃĪ«·¥¤Öµo¥Í§ÜÃĩʪº²{¶H¡A³oÓ°ÝÃD¥Ø«e¤w¸g¥i¥H§JªA¡C ¦Óªø®Ä«¬¤zÂZ¯À»Ý¨C¶g©w´Á¬I¥´ªº¤è¦¡¡AÁö°§C¤F´NÂ媺«K§Q©Ê¡A¨Ã¥B¥i¯à³y¦¨¤@¨Ç°Æ§@¥Î¼vÅT¥Í¬¡«~½è¡A¦ýÀøµ{®É¶¡©T©w¡A1¦~«á§Y¯àµ²§ôªvÀø¡A¤£¶È¨S¦³§ÜÃÄ©Ê°ÝÃD¡B¯à¹F¨ì«ùÄòªº§K¬Ì½Õ±±¥~ |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/31 ¤U¤È 02:16:58²Ä 37 ½g¦^À³
|
¤µ«ÊÃö,©ú¦~ªº´Á³\. 6446¤W¿³Âd»ù206¤¸,¥H¤µ¤Ñ¦¬½L»ù135¤¸p,¶^´T¬°¬ù35%,À³Åý¤H¥¢±æ. ¤£¹L§O¦Ç¤ß,©ú¦~±q¹s¶}©l,«÷°fÂà³Ó,¥Ø¼Ðº¦´T100%. ¯¬¦U¦ì¤ß·Q¨Æ¦¨,¦Ï¦~¦æ¤j¹B. |
|
|
·|û¡GOOXX10022393 µoªí®É¶¡:2014/12/31 ¤U¤È 02:08:09²Ä 36 ½g¦^À³
|
ÃĵØP1101ÁÙ¨S¤W¥«¶}½æ, ½Ð°Ý¦³¨º®a°|©Ò¥i¥H®³¨ìÃÄ©O? ÁÂÁÂ. |
|
|
·|û¡Gª÷¨©¨©10138973 µoªí®É¶¡:2014/12/31 ¤U¤È 01:55:41²Ä 35 ½g¦^À³
|
¦U¦ì¤j¤j¦n¡G¥»¤H¦³¨â¦ìªB¤Í¿©±wC¨x¡A±µ¨ü«Øij¥h¬I¥´ÃĵØP1101ªvÀø®ÄªG¨ôµÛ¡A©Ò¥H¦b¦¹»P¦U¦ì¤À¨É¡A¤]©IÆ~¦U¦ì¤j¤jY¦³¿ËªB¦n¤Í¿©±wC¨x©ÎB¨x¡A½Ð«Øij¥LÌ¥h±µ¨üªvÀø¡A¨Ã¯¬ºÖ¥LÌ«ì´_°·±d¤H¥Í¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/31 ¤W¤È 11:32:30²Ä 34 ½g¦^À³
|
¥Ó½Ð°ª¬ì§Þ¨Æ·~®Öã¨ç¥»¤ë¸É¥ó, ¤µ¦~ªí²{¤£¦p¹w´Á,¦ý©ú¦~¤´È±o´Á«Ý. °£µ¥«Ý¥~,ÁÙ¬Oµ¥«Ý,ÀR«Ý¨Îµ. |
|
|
·|û¡G±¶10137165 µoªí®É¶¡:2014/12/31 ¤W¤È 10:27:33²Ä 33 ½g¦^À³
|
ºG |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/19 ¤W¤È 11:25:43²Ä 32 ½g¦^À³
|
6446©ó¤µ¦~¤C¤ë¦V¸gÀÙ³¡¤u·~§½¥Ó½Ð°ª¬ì§Þ¨Æ·~®Öã¨ç,À³¹wp©ú¦~1¤ë¥÷®Öã, YµL·N¥~,IPO¦æµ{À³©ó©ú¦~²Ä¤G©u§¹¥þ. |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2014/12/18 ¤W¤È 07:34:39²Ä 31 ½g¦^À³
|
¥H¨CÓ¤H¬°¤¤¤ß ¥h¼vÅT¨Ã䪺¨CÓ¤H ¬Ý¬O½Ö¥D¾É¤F³oÓ¤£¤½¤£¸qªºÃÒ©Òµ| ¥Î¿ï²¼¨î¤î§a ¥þ±¨îµô |
|
|
·|û¡Gbill10135881 µoªí®É¶¡:2014/12/18 ¤W¤È 12:08:30²Ä 30 ½g¦^À³
|
°ê¥ÁÄÒ°µ²yµ¹¥Á¶iÄÒ 3¦~½w½Ä è¦nÅý¤p^¦b2016¤jÅ㨤⠥þÅé¤H¥Á±j¤OºÊ·þ¥Á¶iÄÒ¤p^¦C¤JÁ`²Î¤j¿ïºn¬F¨£~!~ |
|
|
·|û¡G¤p°¨10135228 µoªí®É¶¡:2014/12/17 ¤U¤È 11:06:35²Ä 29 ½g¦^À³
|
ÄêÄêÄê¬F©² ½Ð¤j®a¥Î¿ï²¼¤j¤Oªº¨îµô¥¦!! |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/17 ¤W¤È 08:37:51²Ä 28 ½g¦^À³
|
³¯¼w»Ê¡G¥Í§Þµo®i¶Õ¦b¥²¦æ 2014¦~12¤ë17¤é 04:10 °OªÌÀs¯q¶³¡B¶ÀªY¡þ·s¦Ë¡B®ç¶é¾÷³õ³ø¾É ¤j³°®ü¨ó·|·|ªø³¯¼w»Ê¬Q¡]16¡^¤é°Ñ³X·s¦Ë¬ì¾Ç¤u·~¶é°Ï¡A°£²âÅ¥¥Í§Þ¼t°Ó²³ø¡A¥L±j½Õ¡A¤j¼Æ¾Ú·í¹Dªº®É¥N¡A¥Íª«¬ì§Þµo®i¶Õ¦b¥²¦æ¡C¥Lµn¾÷«eÁ`µ²¥»¦¸³X¥x¦æµ{¡A°£´Á«Ý¨â©¤¦~»´¤H»P¤¤¤p¥ø·~¦³§ó¦h¥æ¬y¡A¤]§Æ±æ¨â©¤¦b¦Û¥Ñ¶T©ö¦³§ó¦h¬ð¯}¡C ³¯¼w»Ê¦¹¦æ³X¥x¦@8¤Ñ7©]¡A¬Q¤é³Ì«á¤@¯¸¨ì¦Ë¬ì¡A¥L¦^¾Ð10¦~«eº«×¨ì¦Ë¬ì¡A¬O·í®É·s¦Ë¥«ªø½²¤¯°í±µ«Ý¡A¨º®É´¹¶ê±q6¦Tµo®i¨ì8¦T¡A¥h¦~¥x¿n¹q¸³¨Æªø±i©¾¿Ñ±a¥L°ÑÆ[«n¬ì¡A´¹¶ê¤w¸gµo®i¨ì16¦T¡C ¦ý¥L»¡¡G¡u²{¤µªº«ÂIÀ³¸Ó©ñ¦b¥Íª«¬ì§Þ¡A¦]¬°¤HÃþªº°·±d¤ñ¤°»ò³£ÁÙ«n¡C¡v³o¦¸¯S§O¨ì¦Ë¬ì¡A§Æ±æ¯à°÷¤F¸Ñ¥ÍÂå¬ÛÃö²£·~¡C ³¯¼w»Êªí¥Ü¡A¬ü°êÁp¨¹¬F©²¦b70¦~¥N«ª÷¥´³y¥Íª«¬ì§Þ¡A¤£¹L·í®É¬ì§Þ¡B¸ê·½¤£¨¬¡A¿ð¿ðµLªk¬ð¯}¡A¦p¤µ®É¾÷¤w¸g¦¨¼ô¡A¥þ¤HÃþªº°·±dÀ³´£¤É¨ì·sªº¤ô¥¡A¥x¡B®ü¨â©¤¤]À³¸Ó¦p¦¹¡A¤j³°Áö§ë¸ê¤j¶qª÷¿ú¡Bª«¸ê¬ã¨s¬ì¾Ç¡A¨â©¤¥æ¬yÁÙ¤£°÷¡C ³¯¼w»Ê¬Q¤éÅ¥¨ú²³ø®É®i²{°ª«×¿³½ì¡A¤£®É´£¥X°ÝÃD¥H¤F¸Ñ§ó¦h²Ó¸`¡A¤]¦³·~ªÌ·í±«P½Ð¨ó§U¶i¤J¤j³°¥«³õ¡A¦ý¥L¨S¦³ª½±µ©Ó¿Õ¡A¥u¬O¸ß°Ý§ë¸êª÷ÃB¡B²£«~¶i«×µ¥²Ó¸`¡C ³¯¼w»Ê¬Q¤é¤W¤È°Ñ³X¦Ë¬ì¤F¸Ñ¥ÍÂå¡A°¨^¤EÁ`²Î¤]¦b®t¤£¦h®É¶¡¥X®u·s¦Ë¥ÍÂå²£·~¤Î¨|¦¨¤¤¤ß¶}¹õ¨å§¡A¨â¤H¬Û¶Z¤£¨ì10¤½¨½¡C ´CÅé°l°Ý³¯¼w»Ê¬O§_¦³¾÷·|©M°¨^¤EÁ`²Î¨£±¡A³¯¼w»Ê§C½Õ»¡¡G¡u³o¤£¬O§Ú¯àªíºAªº¡C¡v¦Ü©ó¬Q¤Ñ¶Ç¥XµLªk»P·s¬ì¥x¥_¥«ªø¬_¤åõ¨£±¡A¥L«h±j½Õ¡AY¥xÆWÄ@·N°Q½×¨â©¤¸gÀÙµo®i¡A³£«ÜÄ@·N½Í½×¡A¦U¬É¤]ª¾¹D¤¤°ê¹ï¥x¿Wªº¥ß³õ¡A¨Ã»¡¡G¡u§Ú̦³©³½u¡A§Æ±æÂù¤èªº°Q½×¬O¦³§Q©ó¨â©¤µo®i¡v¡C ³¯¼w»Ê«ü¥X¡AY¬_¤åõ¦³¿³½ì¡A¯S§O¬O°w¹ï¥x¥_¥«»P¤j³°µo®i¦X§@¡A¥L«ÜÄ@·N¨£±¡A¬_¤åõ¥¼¨ÓY¦³¾÷·|¨ì¥_¨Ê¡AÂù¤è¥i¥H¨£±°Q½×¡C ³¯¼w»Ê¦bµn¾÷«e¨ü³X®Éªí¥Ü¡A³X¥x¦æµ{Åý¥L¯d¤U²`¨è¦L¶H¡A¦P®É¤]¹ï©ú¦~¦p¦ó¥[±j¨â©¤¥æ¬y¡A¤×¨ä¬O»P¦~»´¤H¡B¤¤¤p¥ø·~¥æ¬y¦³¨Çºc·Q¡C³¯¼w»Ê¤]ªí¥Ü¡A¥¼¨Ó±N«ùÄò¥[±j¨â·|Ápô¡FÁöµMªA¶T¨óijÁÙ¦bµ¥«Ý¥Í®Ä¡A¦ý³f¶T¤w¸g¦P¨B¦b¥_¨Ê¶}½Í¤F¡A¤]¹w¯¬½Í±o§ó¦n¡C¥L«ü¥X¡A¤j³°ªººÖ«Ø¡B¼sªF»P¤Ñ¬z¡A³£©M¤W®ü¤@¼Ë¦³¦Û¥Ñ¶T©ö¹êÅç°Ï¡A¤]§Æ±æ¥xÆW¤]¦³Ãþ¦ü¹êÅç°Ï»P¤j³°¤¬°Ê¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/15 ¤U¤È 06:56:39²Ä 27 ½g¦^À³
|
¡i¸gÀÙ¤é³ø¢¬°OªÌ¶À¤å©_¢¬§Y®É³ø¾É¡j 2014.12.15 12:36 pm ÃĵØÃÄ¡]6446¡^¤µ¤é«Å¥¬¡A¸Ó¤½¥q¬ãµo¤¤ªº¤û¥ÖÅ~·sÃÄKX01/KX2-391¤w©ó12¤é¥¿¦¡¦V¥xÆW½Ã¥ÍºÖ§Q³¡¹«~ÃĪ«ºÞ²z¸p¡]TFDA¡^»¼¥æ¤HÅéÁ{§É¸ÕÅç¼f¬d¡]IND¡^¥Ó½Ð¡A«ÝTFDA®Öã«á±N¶i¤J¤@/¤G´Á¤HÅéÁ{§É¸ÕÅç¡A¹wp©ó2015¦~²Ä¤T©u§¹¦¨¡C ¤û¥ÖÅ~¥Dn¬O¦]¬°¨¤½è²ÓM¤Æ²§±`¡B·s¦åºÞ§Î¦¨²§±`¡A¥H¤Îµoª¢©Î§K¬Ì²§±`©Ò¤Þ°_¡A¦]¦¹¥Ø«eªºªvÀø¤èªk¤]¥HªvÀø¤Wz¤TºØ¯f¯gµÛ¤â¡CµM¦Ó¡A¥«±¤W²{¦³ªºÃĪ«¤£½×¬O¥~¥Î»s¾¯¡B¤fªA©Î¬Oª`®g¥ÎÃÄ¡A³£¥u¯àªvÀø³æ¤@¯f¯g¡CÃĵØÂåÃĤ޶iªºÔ¿ï·sÃÄKX01¡A¬°¤@¤Æ¾Ç¦X¦¨¤p¤À¤lÃĪ«¡A¥Dn¥i§í¨îSrc»²?©M·LºÞ³J¥Õ¤G»EÅé¡]tubulin heterodimers¡^¡A¦Û¬ü°êKinexÃļt¨ú±o±ÂÅv«á¡A¥[¥H¶}µo§ï¨}¬°·s¤@¥N³n»I¾¯«¬¡A¯à°÷¨³³tº¯³z¥Ö½§¥B§Ö³t§l¦¬¡AKinexÃļt¦bÅé¥~¸ÕÅçµo²{¨ä¦P®É¨ã¦³§Ü¼W´Þ©Ê(antiproliferative)¡A¯à§í¨î¤H¨¤½è²ÓM(keratinocyte)ªº§Î¦¨»P¥Íªø¡A¦³®Äªº§í¨î§K¬Ì²ÓM²¾°Ê¡A¥H¤Î§Ü·s¦åºÞ§Î¦¨(neovascularization)µ¥§@¥Î¡A¦]¦¹¹w¦ôKX01¦bÁ{§É¸ÕÅ礤±NÃÒ¹ê¹ï¤û¥ÖÅ~¨ã¥þ±©ÊÂåÀø®ÄªG¡C ÃĵØÂåÃĸ³¨Æªøݬì¾Çªø¸â«C¬hªí¥Ü¡A¡u§ÚÌ«Ü°ª¿³¥i¥H¸òKinex¦@¦P¦X§@KX01·sÃĶ}µopµe¡A¦b¨â®a¤½¥qªº±M·~¹Î¶¤§V¤O¤U¡A¦¨¥\ÂX®iKX01ªºÁ{§ÉÀ³¥Î¡C¡vÃĵØÂåÃÄÁ`¸g²zªL°êÄÁ¤]«ü¥X¡A¡u§ÚÌ«D±`´Á«ÝKX01¦bªvÀø¤û¥ÖÅ~ªºÁ{§ÉÀ³¥Îµo®i»P¦¨®Ä¡A¤]«D±`ź¶Æ¯à²v¥ý¦¹·s¾÷¨î·sÃÄKX01¾É¤J¦b¤û¥ÖÅ~ªºªvÀøÀ³¥Î¤W¡C¡v KinexÂå¾ÇªøRudolf Kwan¸É¥R»¡¡G¡uKX01³n»I¾¯«¬¨ã¦³Àu²§ªº§@¥Î¾÷¨î¡A±N·|¬O¦³®ÄªvÀø¤û¥ÖÅ~ªº¤@ºØ·s¤è¦¡¡C¡vKinex¬ì¾ÇªøDavid Hangauer«hªí¥Ü¡G¡uKX01ªºª«²z¯S©Ê¨Ï¨ä¯àÂǥѧ½³¡¶î©Ùªº³n»I°t¤è¡A¨³³tº¯³z¨ì¥Ö½§²Õ´¡A§ÚÌ«Ü°ª¿³KX01¯àÂX¤j¨ìªvÀø¤û¥ÖÅ~»P¨ä¥L¥Ö½§¯fªºÁ{§ÉÀ³¥Î¡C¡v ¥Ø«eKX01¤w¥Ñ¬ü°êKinexÃļtÀò±oFDA¤G´ÁÁ{§É®Öã°µ¬°ªvÀø¥Ö½§Àù·sÃÄ¡A¨¬¥iÃÒ¹êKX01¹ï¤HÅ骺¦w¥þ©ÊµL¸·¡A¹w´Á±N¥i¤j´T´î¤ÖÃĵØÂåÃĦb¤@/¤G´ÁªºÁ{§É¸ÕÅç§ë¸ê·ÀI¡A¹wp2015¦~²Ä¤T©u§¹¦¨¡C ®Ú¾ÚDatamonitor¤½¥q¹w´ú¡A¥þ²y¤û¥ÖÅ~¥«³õ±q2009-19¦~ªº½Æ¦X¼Wªø²v¬°5.5%¡A¦Ü2019¦~ªº¥«³õ³W¼Ò¥i¹F47»õ¬ü¤¸¡A¤¤°ê¬°¥Dn¥«³õ¤§¤@¡C¤¤°ê¤Hªºµo¯f²v¬ù¦³0.8%¥ª¥k¡A¦ôp¦³¶W¹L¤d¸U¥H¤Wªº±wªÌ¡AÃĵØÂåÃľ֦³KX01¤j¤¤µØµ¥¦a°Ïªº±ÂÅv¡A¦³¾÷·|·m§ð¤¤°ê¤û¥ÖÅ~¥«³õ°Ó¾÷¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/15 ¤U¤È 06:45:21²Ä 26 ½g¦^À³
|
ÃĵØÃÄ ¤û¥ÖÅ~ÃÄ¥Ó½ÐÁ{§É¸ÕÅç ¡iÁp¦X±ß³ø¢¬°OªÌ®}·ü¶v¡þ¥x¥_³ø¾É¡j 2014.12.15 04:25 pm ¿³Âd¥Í§ÞªÑÃĵØÃÄ(6446)¬ãµo¤¤ªº¤û¥ÖÅ~·sÃÄKX01/KX2-391¤w©ó12¤é¥¿¦¡¦V¥xÆW¹«~ÃĪ«ºÞ²z¸p»¼¥æ¤HÅéÁ{§É¸ÕÅç¼f¬d¥Ó½Ð¡A«Ý®Öã«á±N¶i¤J¤@/¤G´Á¤HÅéÁ{§É¸ÕÅç¡A¹wp©ó2015¦~²Ä¤T©u§¹¦¨¡C ÃĵØÃĤ޶iªºÔ¿ï·sÃÄKX01¡A¦Û¬ü°êKinexÃļt¨ú±o±ÂÅv«á¡A¥[¥H¶}µo§ï¨}¬°·s¤@¥N³n»I¾¯«¬¡A¯à°÷¨³³tº¯³z¥Ö½§¥B§Ö³t§l¦¬¡C ÃĵØÃĸ³¨Æªø¸â«C¬h«ü¥X¡AKinexÃļt¦bÅé¥~¸ÕÅçµo²{¨ä¦P®É¨ã¦³§Ü¼W´Þ©Ê¡A¯à¦³®Äªº§í¨î§K¬Ì²ÓM²¾°Ê¡A¥H¤Î§Ü·s¦åºÞ§Î¦¨µ¥§@¥Î¡A¦]¦¹¹w¦ôKX01¦bÁ{§É¸ÕÅ礤±NÃÒ¹ê¹ï¤û¥ÖÅ~¨ã¥þ±©ÊÂåÀø®ÄªG¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/15 ¤W¤È 07:38:50²Ä 25 ½g¦^À³
|
¥ý³ø§Aª¾. 2015¨È¬w³Ì¤jªº¥Íª«¬ì§Þ¤j®i ®i¥X®É¶¡ 2015/7/23(¥|) - 7/26(¤é) ¶i¥X³õ®É¶¡ ¶i³õ®É¶¡¡G2015¦~7¤ë21¤é(¤G)¡B7¤ë22¤é(¤T) ¥X³õ®É¶¡¡G2015¦~7¤ë26¤é(¤é)(±ß¤W11ÂI«e³s©]¥X³õ) ®i¥X¦aÂI ¥x¥_¥@¬É¶T©ö¤¤¤ß«n´ä®iÄýÀ] (¥x¥_¥««n´ä°Ï¸g¶T¤G¸ô1¸¹) ¥D¿ì³æ¦ì ¤¤µØ¥Á°ê¥Íª«²£·~µo®i¨ó·| ¤¤µØ¥Á°ê®iÄýº[·|ij°Ó·~¦P·~¤½·| ®i¬L°ê»Ú¥ø·~ªÑ¥÷¦³¤½¥q P1101 - PEGªø®Ä«¬£\¤zÂZ¯À·sÃÄ ¼t°Ó¦WºÙ¡GÃĵØÂåÃĪѥ÷¦³¤½¥q ²£«~¤ÀÃþ¡GÂåÃÄ»PÂåÀø Åu¦ì¸¹½X¡GJ407¡B409 http://www.bioclub.com.tw/visitorExhibitor.asp |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/15 ¤W¤È 07:36:35²Ä 24 ½g¦^À³
|
¥x·s§ëÅU¨ó²z¶À¤å²M«ü¥X¡A¨ü¨ì¤WÂd¥«³õªñ´Á¥Í§ÞªÑ±j¶Õ¤Wº¦±a°Ê¡A¨Ï±o¤W©P¿³Âd¥«³õ¥Í§ÞÂåÀø·~¦¨¥æ¶q«ùÄò¼öµ¸¡C¥¼¨Ó¦³¤£¤Ö«¶q¯Å¥Í§Þ¤½¥q§Y±N§ë¤J¸ê¥»¥«³õ¡AÀHµÛ°ê¤º·sÃĶ}ªáµ²ªG¡A¥i¯}°£¥~¬É»{¬°¶È¦³¥»¹Ú¤ñºÃ¼{¡A¥¼¨Ó·sÃĤ½¥q±N¦³¹ê»ÚÀ禬¤ÎÀò§Q°^Äm¡A´Â°ê»Ú¤j«¬»sÃļt¦¨ªøy¸ñ«e¶i¡C ¤£¥Î§@²Ä¤@, ¥un§@°ß¤@ |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/12 ¤U¤È 03:10:28²Ä 23 ½g¦^À³
|
¼È¤£½×¥þ¥@¬É¤zÂZ¯À²£«~¦³¦h¤Ó, YªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)ªø®Ä®ÄªG½T»{¡A ¹F¨ì¨CӤ르¤@°w¥B°Æ§@¥Î§ó§Cªº¥Ø¼Ð,«h: 1.Y¥HÃÄ»ù©w»ù¬Û¦P,¬O§_·|¨ú¥Nì¤@©P¤@¦¸,ªø®Ä«¬¤zÂZ¯ÀªºÉ]³õ,³o¬O¸Ó«ä¦Òªº°ÝÃD, 2.«áÄòCML.ET.PMF,HBV,HCV-G1,HCV-G2µ¥Pipeline¬O§_§ó¯à¦b¬J¦³°ò·¡¤W¥[³t¬ãµo. 3.¤½¥q2016¤§«á¤T¦~p¹º,³£¤v³W¹º§¹¦¨,Y¥[¤W°ê»Ú¤j¼tµ¦²¤Áp·ù©Î¨ÖÁʾ÷·|,§Aı±o¦¨¥\¾÷·|¦³¦h¤j. The best is yet to come |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2014/12/11 ¤U¤È 02:45:12²Ä 22 ½g¦^À³
|
¥Ø«e¥þ²y¥Dnªº«²Õ¤zÂZ¯À²£«~¤À¬°¨â¤jÃþ¡G¡³1 µu®Ärh-IFN¡A¥Dn¬°rhIFN-£]¡A¥]¬ABiogen Idec¤½¥qªºAvonex¡]IFN-£]1a¡^¡BMerck Serono ¤½¥qªºRebif¡]IFN-£] 1a¡^¡BBayer¤½¥qªºBetaferon/Betaseron¡]IFN-£]1b¡^¤ÎNovartis¤½¥qªºExtavia¡]IFN-£]1b¡^¡A¡³2 ªø®Ärh-IFN¡X¡XPEG rh-IFN¡A¦³Roche¤½¥qªºPegasys¡]PEG IFN-£\ 2a¡^©M¬ü°êMSD¤½¥qªºPeg-Intron¡]PEG IFN-£\ 2b¡^¡A¥H¤Îªñ´ÁÀò§åªºPlegridy¡]»E¤A¤G¾J¤zÂZ¯À£]-1a¡^¡C ±q¾AÀ³Äp¨Ó¬Ý¤À¬°¨â¤jÃþ¡G1¡B¦hµo©Êµw¤ÆÄp¡G¥Dn²£«~¦³Avonex¡]IFN-£]1a¡^¡BRebif¡]IFN-£] 1a¡^¡BBetaferon/Betaseron¡]IFN-£]1b¡^¤ÎExtavia¡]IFN-£]1b¡^¡A¥H¤Î2014¦~Àò§åªºPlegridy¡]»E¤A¤G¾J¤zÂZ¯À£]-1a¡^¡F2¡B¤A¨x©M¤þ¨x¡GPegasys¡]PEG IFN-£\ 2a¡^©MPeg-Intron¡]PEG IFN-£\ 2b¡^¡C 2003-2013¦~«²Õ¤zÂZ¯À¦b¥þ²yªº¾P°âÃB¥Ñ45.1»õ¬ü¤¸¼W¥[¨ì91.5»õ¬ü¤¸¶È¦¸¤_«²Õ¤H¯Ø®q¯À¡A¬°¥þ²y²Ä¤G¤j«²Õ³J¥ÕÃĪ«¡A¦~´_¦X¼Wªø²v¬°7.33%¡C 2013¦~¥þ²y«²Õ¤zÂZ¯Àªº¾P°âÃB¬°91.5»õ¬ü¤¸¡]¶È²Îp«~µPì¬ãÃÄ¡^¡A¨ä¤¤Biogen Idec¤½¥qªºAvonex¡]IFN-£]1a¡^¥H30.1 »õ¬ü¤¸ªº¾P°âÃB¦ì©~º¦ì¡A¥e¾Ú33%ªº¥«³õ¥÷ÃB¡FMerck Serono ¤½¥qRebif¡]IFN-£]1a¡^ªº¾P°âÃB¬°25.9 »õ¬ü¤¸¡A¥H28%ªº¥«³õ¥e¦³²v¦ì©~²Ä¤G¡FBayer ¤½¥qªºBetaferon/Betaseron¡]IFN-£]1b¡^¾P°âÃB¬°14.4 »õ¬ü¤¸¡A¥«³õ¥÷ÃB¬°16%¡FRoche¤½¥qªºªø®Ä¤zÂZ¯ÀPegasys¡]PEG IFN-£\2a¡^¾P°âÃB¬°14.6»õ¬ü¤¸¡A¥«³õ¥÷ÃB¬°16%¡F¬ü°êMSD ¤½¥qªºªø®Ä¤zÂZ¯ÀPeg-Intron¡]PEG IFN-£\2b¡^¾P°âÃB¬°5»õ¬ü¤¸¡A¥«³õ¥÷ÃB¬°5%¡C |
|
|
·|û¡G¶À¤jÄ_10132519 µoªí®É¶¡:2014/12/11 ¤W¤È 10:26:59²Ä 21 ½g¦^À³
|
´¿©v»Ê FB¶}¤F ¤@¤H¤@«H ¶Ç¹FªÑ¥Á¤ßÁn.https://www.facebook.com/TsengMingChung |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/11 ¤W¤È 08:56:53²Ä 20 ½g¦^À³
|
¤U©P¤T¥ß°|שμo¤j¤á±ø´Ú,¾÷²v«Ü¤j. |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/10 ¤U¤È 04:45:10²Ä 19 ½g¦^À³
|
¦^Àɾã²z,¥¼¹Á¤£¬O¤@¥ó¦n¨Æ,¦b¤j¤á±ø´Ú¥¼¼o¤î¤§«e,¦~©³¿³Âd¦ÛµM¤HÃÒ©Òµ|½æÀ£Âà±b,²z©Ò·íµM. ..... ªvÀøPV¥ÎP1101¥¿©ó¼Ú¬ü¦P¨B¶i¦æÁ{§É¤T´Á¸ÕÅç¡A¸Ô²ÓÁ{§É¸ÕÅç¶i«×³£¤w¦b¥þ²yÁ{§É¸ÕÅçºô¯¸¡]www.clinicaltrials.gov¡^¡A¥H¤ÎAOP¤½¥qPROUD PV Studyºô¯¸¡]www.proud-pv.com¡^¤½¥¬¡C http://translate.google.com.tw/translate?hl=zh-TW&sl=en&u=http://www.proud-pv.com/&prev=search |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2014/12/10 ¤U¤È 04:11:44²Ä 18 ½g¦^À³
|
Á`¸g²zªL°êÄÁ¨Ã«ü¥X¡AP1101·íªì´N³]p¥H¥|Ó¬P´Á¬I¥´¤@¦¸¬°¥Ø¼Ð¡A³o¤]¬O¹L¥h¤Q¾l¦~¨Ó°ê»Ú¦U¤jÃļt¿n·¥°l¨Dªº¥Ø¼Ð¡A³z¹L¦¹¦¸ªº©µªø¸ÕÅç²×©óÃÒ¹êP1101¯à¦¨¥\¹F¨ìªø´Á®ÄÀø¥Ø¼Ð¡A³o¬OPV¯e¯f¥v¤Wªº«¤j¬ð¯} P1101·íªì´N³]p¥H¥|Ó¬P´Á¬I¥´¤@¦¸¬°¥Ø¼Ð¡A³o¤]¬O¹L¥h¤Q¾l¦~¨Ó°ê»Ú¦U¤jÃļt¿n·¥°l¨Dªº¥Ø¼Ð Ãĵذµ¨ì¤F¤F |
|
|
·|û¡G§õÁ`²Î10135593 µoªí®É¶¡:2014/12/10 ¤U¤È 02:18:53²Ä 17 ½g¦^À³
|
¹ï¤@¨ÇµLª¾ªÌ§Ú们µ¹»P¦P±¡ ¦bªvÀø¤@¦~«á½Õ¾ã¦Ü¨C¥|¶gµ¹ÃĤ@¦¸¡A¨ä¤¤³¡¤À¸ÕÅç±wªÌ¤w«ùÄòÀøµ{ªø¹F¥|¦~¡C ªvÀø¤@¦~«á ½Õ¾ã¦Ü¨C¥|¶gµ¹ÃĤ@¦¸ ¬O²Ä¤@¦~´î¤Ö ÁÙ¬O²Ä¤G¦~ ÁÙ¬O¥»¨Ó²Ä¤@¦~ªv·U ¦³¨Ç¤H»Ý²Ä¤G¦~ªv·U Ä@¥L̲Ĥ@¦~´N³Q P1101ªv·U |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/12/10 ¤U¤È 02:11:23²Ä 16 ½g¦^À³
|
¤F¸Ñ. ·PÁÂ. |
|
|
·|û¡G¦sªÑP´I10136213 µoªí®É¶¡:2014/12/10 ¤U¤È 01:46:06²Ä 15 ½g¦^À³
|
±NAOP2014ª`®g¶g´Á§ó§ï¬°¡u¨C¥|¶g¤@¦¸¡v¡C¥»¸ÕÅ窺³æ¦¸ÃÄ«~¾¯¶q¦bÅܧóª`®g¶g´Á«á¨S¦³§ïÅÜ¡A¦]¦¹±wªÌ¤§AOP2014Á`¼ÉÅS¾¯¶q´î¤Ö¬ù¤@¥b-->¦b§Ú¬Ý¨Ó ³o¥y¸Ü³Ì«n ¦Ó¥Bµ²½×¬O"±wªÌ¦å²G¤¤¬õ¦å²y«ü¼Æ¤´ºû«ù¦b¥¿±`ª¬ºA" ¹ï¥Í²£ªÌ¦Ó¨¥, ·íµM©Ò»Ý´£¨Ñ²£¯à¶V§C¶V¦n, ¦]¬°ªí¥Üª½±µ¶¡±µ¦¨¥»³£¥i¥H°->§A³o¥y¸Üµ´¤j³¡¤À«Øºc¦b P1101¥un©w»ù½Õ¬°ì¥ý³]©wªºdouble,§Y«K²£¯à¶È¤@¥b,¥i¥H±o¨ì¤@¼Ëªº¥«³õ(2*0.5=1)¦ý¬O³oºØpºâªk¥»¨´N¤£¦X²z ¦¹¥~¥ÎÃĶq´î¥b¸òÃĦ¨¥»´î¥b¬O¨â½X¨Æ... ³o¦b¦ô¨u¨£¯f¯à¹ïÃļt²£¥Í¦h¤Öeps¤w¸g¬O¶W¯Å¤jªºÅܼƤF §Ú»¡ªº³o¥y¸Ü´N¬OÁ¿¹w¦ô®É·|¦³¶W¤jÅÜ¼Æ ¨Ã¤£¬O¤°»òtµû |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/12/10 ¤W¤È 11:58:41²Ä 14 ½g¦^À³
|
¤p^¤j¶K¤åµ²½×¤¤®¼«nªº¨â¥y: 1. ´î¤Öª`®gÀW²v¤£·|¾ÉP¥ÎÃĵL®Ä¡A¤Ï¦Ó¥i©úÅã´£°ª±wªÌ@¨ü©Ê¡C 2. JAK2°ò¦]Åܲ§¶q¥i«ùÄò°§CÅã¥Ü¤zÂZ¯Àªº¼ÉÅS®É¶¡¦Ó«D¤zÂZ¯Àªº¥ÎÃľ¯¶q¡A¬°»¤¾É¤À¤l¤ÏÀ³ªº«n¦]¼Æ¡C ¨CºØÃij£·|¦³¨ä³Ì¨Î¥ÎÃĶq,¨Ã«D¥Î¶q¶V¦h´N¶V¦n. ³o«h·s»DÁ¿ªº¬O"¥ÎÃĶq(¦¨¥»)´î¥b¦Ó±o¨ì§ó¨Î®ÄªG",¦b§Ú¬Ý¬O100%¥¿±,Y¯à¬Ý¥Xt±¸ÑŪ¹ê¦b¬O«Ü©_©Çªº¤@¥ó¨Æ. |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/12/10 ¤W¤È 11:46:28²Ä 13 ½g¦^À³
|
´«Ó»¡ªk, §Ú»{¬°: ¥«³õ¤j¤pn¬Ý³Ì²×ÃÄ®Ä/©w»ùµ¦²¤»P¥«³õ±µ¨ü«×,¦Ó¸òÁ{§É¥ÎÃĶqªºÅܰʬOµLÃöªº. ¦b¤@¼ËÀø®Äªº«e´£¤U, ¹ï¥Í²£ªÌ¦Ó¨¥, ·íµM©Ò»Ý´£¨Ñ²£¯à¶V§C¶V¦n, ¦]¬°ªí¥Üª½±µ¶¡±µ¦¨¥»³£¥i¥H°. |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/12/10 ¤W¤È 11:30:23²Ä 12 ½g¦^À³
|
"²£¯à"¶È°Q½×¨ì"¶q", "¥«³õ"¤w¸g¬O"²£¯à"X"ÃÄ»ù" P1101¥un©w»ù½Õ¬°ì¥ý³]©wªºdouble,§Y«K²£¯à¶È¤@¥b,¥i¥H±o¨ì¤@¼Ëªº¥«³õ(2*0.5=1) ÃÄ»ùµ¦²¤²o¯A¤Ó¦h¦]¯À,²{¦b°Q½×ÁÙ¤Ó¦,ÁÙ¬Oµ¥¦³¼v¤l¦A»¡§a~~ |
|
|
·|û¡G¦sªÑP´I10136213 µoªí®É¶¡:2014/12/10 ¤W¤È 11:20:36²Ä 11 ½g¦^À³
|
²£¯à¶È»Ý¹Fì¹w´Á¥«³õ»Ý¨Dªº¤@¥b ©M§Ú¼gªº "³o¤£´N¥NªíÃĵئb¦ôp1101 ¥Î¦AªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯gªº¥«³õÀ³¸Óª½±µ¥´¤§é" ªº·N«äÀ³¸Ó«D±`¬Ûªñ§a ³o¦b¦ô¨u¨£¯f¯à¹ïÃļt²£¥Í¦h¤Öeps¤w¸g¬O¶W¯Å¤jªºÅܼƤF....... |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/10 ¤W¤È 10:51:03²Ä 10 ½g¦^À³
|
¥Ñ¸¨«á¨ì»â¥ý. ÃĵØÂåÃÄ·sÃÄP1101©ó¬ü°ê¦å²G¸~½F¦~·|µoªí¡GªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)ªø®Ä®ÄªG½T»{, ¥t¤G®a¥Í²£¤zÂZ¯À®ÄªG¸û®tªº°ê»Ú¼t°Ó,¤@©w®À¦Cµ¥, ²´¥ú©ñ²´¤@ÂI,P1101Y¯à¦¨¥\,«áÄòªºPipeline±N¦³«Ü¤jªº¦¨¥\¾÷²v, ¨º´N¬O¼Éµoªº®É¨è,¤£¥i¤p¬Ý¤½¥qªº¥¼¨Ó¼ç¤O. |
|
|
·|û¡GJM10139061 µoªí®É¶¡:2014/12/10 ¤W¤È 10:10:39²Ä 9 ½g¦^À³
|
¤£¬O§a~ÃÄ»ù³£ÁÙ¨S¥X¨Ó,«ç·|¦³"¤ÖÁȤ@¥b"ªº°ÝÃD? À³¸Ó¸ÑŪ¦¨"²£¯à¶È»Ý¹Fì¹w´Á¥«³õ»Ý¨Dªº¤@¥b,¤£¦Ü©ó¨Ñ¤£À³¨D,¯àÁÈ«oÁȤ£¨ì"§a!! |
|
|
·|û¡G¦sªÑP´I10136213 µoªí®É¶¡:2014/12/10 ¤W¤È 09:55:02²Ä 8 ½g¦^À³
|
³o¯u¬O«Ü¥Ù¬Þªºµ²ªG ------------------------------------------------------------------------ ¦bªvÀø¤@¦~«á½Õ¾ã¦Ü¨C¥|¶gµ¹ÃĤ@¦¸¡A¨ä¤¤³¡¤À¸ÕÅç±wªÌ¤w«ùÄòÀøµ{ªø¹F¥|¦~¡C ¸g¦¹½Õ¾ã«á¡A±wªÌ¦å²G¤¤¬õ¦å²y«ü¼Æ¤´ºû«ù¦b¥¿±`ª¬ºA¡A¥iª¾·s¤@¥Nªºªø®Ä«¬¤zÂZ¯À±µ¨ü«×§ó¦n ------------------------------------------------------------------------ ³o¤£´N¥NªíÃĵئb¦ôp1101 ¥Î¦AªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯gªº¥«³õÀ³¸Óª½±µ¥´¤§é ÃĮīܦn ¦ýªí¥ÜÁȪº¿ún¤Ö............ |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/10 ¤W¤È 07:32:59²Ä 7 ½g¦^À³
|
3177 Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study Program: Oral and Poster Abstracts Session: 634. Myeloproliferative Syndromes: Clinical: Poster II Sunday, December 7, 2014, 6:00 PM-8:00 PM West Building, Level 1 (Moscone Center) Heinz Gisslinger, MD1, Veronika Buxhofer-Ausch, MD2*, Josef Thaler, MD3*, Ernst Schloegl, MD4*, Guenther A. Gastl, MD5, Dominik Wolf, MD6*, Robert Kralovics, PhD7, Bettina Gisslinger, MSc8*, Karin Strecker, MD9*, Alexander Egle, MD10, Thomas Melchardt, MD10*, Sonja Burgstaller, MD3*, Ella Willenbacher, MD5*, Michael Zoerer, PhD11*, Pavla Kadlecova, PhD12*, Oleh Zagrijtschuk, MD11*, Christoph Klade, PhD11* and Richard Greil, MD10 1Department of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria 2Krankenhaus der Elisabethinen Linz, Linz, Austria 3Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria 4Third Medical Department, Hanusch Hospital, Vienna, Austria 5Dep. Internal Medicine V, Haematology & Oncology, Innsbruck Medical University, Innsbruck, Austria 6Department of Hematology, Oncology and Rheumatology, Center of Integrated Oncology Cologne Bonn, University Hospital of Bonn, Bonn, Germany 7CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria 8Department of Internal Medicine I, Division of Hematology and Blood Coagulation, Medical University of Vienna, Vienna, Austria 9Sozialmedizinisches Zentrum Ost - Donauspital, Vienna, Austria 10IIIrd Medical Department, Salzburg Cancer Research Institute, Paracelsus Medical University, Salzburg, Austria 11AOP Orphan Pharmaceuticals AG, Vienna, Austria 12Aprova CRO, Brno, Czech Republic Background AOP2014 is a next generation long-acting pegylated IFN-alpha-2b, consisting predominantly of only one isoform, as opposed to other commercially available pegylated interferons. Due to this property, reduced dosing frequencies, better tolerability, improved compliance and more favorable long-term treatment outcomes in patients with Polycythemia Vera (PV) are expected. The drug has Orphan designation by EMA and FDA and is currently in the phase III stage of development. Study design This phase I/II single arm dose escalation study with cohort extension included 51 patients with PV who could be either cytoreduction therapy naive or pre-treated. AOP2014 was administered subcutaneously in a dose range of 50-540 mcg every two weeks. Main objectives were to define the maximum tolerated dose as well as observe the long term safety and efficacy in terms of normalization of blood parameters and molecular abnormalities (results were already presented at the ASH 2013 annual meeting by Gisslinger et al). The option to switch to an "once every four weeks" schedule has been implemented by the amended protocol for patients who responded well to the treatment and participated in the study for longer than one year. The dose of the study drug had to remain unchanged after the switch, resulting in a decrease (by approx. the half) of the overall exposure to the drug. Outcomes of this switch are presented here. Results Patients (period A, median exposure duration 34 weeks, mean monthly dose 484 mcg) were dosed every two weeks based on the Phase II dosing rules prior having switch option. 33 patients (period B, median exposure duration 12 weeks, mean monthly dose 413 mcg) were dosed every two weeks beyond the first year and, showing benefit from treatment, have been assessed as eligible for switch. 28 patients (period C, median exposure duration 42 weeks) were then switched to once every four weeks schedule (mean monthly dose 221 mcg). Blood parameters were normalized and remained stable following one year of treatment and could be maintained after the switch< |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/10 ¤W¤È 07:25:06²Ä 6 ½g¦^À³
|
AOP©t¨àÃĤ½¥q©ó¬ü°ê¦å²G¸~½F¦~·|µoªíP1101¥Î©óªvÀøPV¤§©µªøÁ{§É¸ÕÅç³ø§i 3177 AOP2014 (¤@ºØ·sªº»E¤A¤G¾J¤zÂZ¯À£\)ªvÀø¯u©Ê¬õ¦å²y¼W¦h¯g(PV)±wªÌ¡A¥Ñ¨C¨â¶g¥Ö¤Uª`®gÅÜ´«¦Ü¨C¥|¶g¥Ö¤Uª`®g¡A¥iºû«ùÀø®Ä¨Ã§ï¶iÃĪ«¬r©Ê¤§²Ä I/II´ÁÁ{§É¸ÕÅç I´º ¤£¦P©ó¨ä¥L¤W¥«¤§¤zÂZ¯À¡AAOP2014¬O·s¤@¥Nªºªø®Ä«¬»E¤A¤G¾J¤zÂZ¯À£\-2b¡A¥Dn¥Ñ³æ¤@²§ºcª«²Õ¦¨¡C¥Ñ©ó¤Wz¯S©Ê¡A¹w´Á¦¹ÃĥΩó¯u©Ê¬õ¦å²y¼W¦h¯g(PV)±wªÌ¡A¥i´î¤Öµ¹ÃÄÀW²v¡B´£°ª±wªÌ@¨ü©Ê¡B§ï¶iÂåÅñ¿í±q©Ê¡A¶i¦Ó¦³§ó¦nªºªø´ÁÀø®Ä¡C¦¹ÃĤw¸gEMA©MFDA®Ö¥i¬°©t¨àÃÄ¡A¥Ø«e¥¿³B©ó²ÄIII´ÁÁ{§É¸ÕÅ窺µo®i¶¥¬q¡C ¬ã¨s³]p ì²ÄI/II´Á³æ²Õ¾¯¶q´£¤ÉÁ{§É¸ÕÅçp¦³51¨ÒPV±wªÌ¡A¥]¬A¥¼´¿©Î´¿¸g±µ¨ü²ÓM´î§íÀøªkªÌ¡CAOP2014¤§¥Ö¤Uª`®g¾¯¶q¡A¤À¥¬©ó¨C¨â¶g50²@§J¦Ü¨C¨â¶g540²@§J¡CìÁ{§É¸ÕÅç¥Dn¥Ø¼Ð¬°½T©wAOP2014³Ì¤j@¨ü¾¯¶q¡A¨ÃÆ[¹îªø´Á¦w¥þ©Ê¥H¤Î¦å²G©M¤À¤l«ü¼Ð¥¿±`¤Æ¤§Àø®Ä(µ²ªG¤w©ó2013¦~ASH¦~·|¥Ñ Gisslingerµ¥µoªí)¡Cì¸ÕÅçpµe®Ñ¸g×¥¿«á¡A©óªvÀø¤ÏÀ³¨}¦n¥B°Ñ»P¸ÕÅç¹F¤@¦~¥H¤W¤§¨ü¸ÕªÌ¡A±NAOP2014ª`®g¶g´Á§ó§ï¬°¡u¨C¥|¶g¤@¦¸¡v¡C¥»¸ÕÅ窺³æ¦¸ÃÄ«~¾¯¶q¦bÅܧóª`®g¶g´Á«á¨S¦³§ïÅÜ¡A¦]¦¹±wªÌ¤§AOP2014Á`¼ÉÅS¾¯¶q´î¤Ö¬ù¤@¥b¡CÅܧóª`®g¶g´Á«á¤§¸ÕÅçµ²ªG³ø§i©ó¦¹¡C µ²ªG A´Á¶¡ (¥ÎÃĮɶ¡¤¤¦ì¼Æ34¶g¡A¥§¡¨C¤ë¾¯¶q484 mcg)¡G¨ü¸ÕªÌ°ò©ó¥ý«e²ÄII´ÁÁ{§É¸ÕÅ礧µ¹ÃÄì«h¡A±µ¨ü¨C¨â¶g¤@¦¸¤§ª`®g¶g´Á¡CB´Á¶¡¡A33¨Ò¨ü¸ÕªÌ(¥ÎÃĮɶ¡¤¤¦ì¼Æ12¶g¡A¥§¡¨C¤ë¾¯¶q413 mcg)¡G§¹¦¨²Ä¤@¦~¸ÕÅ礧«á¡A¤´¨C¨â¶gª`®g¡A¨ü¸ÕªÌ¶·Åã¥Ü¨ü¯q©óªvÀø¡Aµû¦ô¨ä¬O§_¾A¦XÅܧóª`®g¶g´Á¡CC´Á¶¡¡A28¨Ò¨ü¸ÕªÌ(¥ÎÃĮɶ¡¤¤¦ì¼Æ42¶g)¡GÅܧóª`®g¶g´Á¦Ü¨C¥|¶gª`®g(¥§¡¨C¤ë¾¯¶q221 mcg)¡C±µ¨üAOP2014ªvÀø¤@¦~«á¡A¦h¼Æ¨ü¸ÕªÌªº¦å²G«ü¼Ð¥i¥¿±`¤Æ¨Ã«O«ùéw¡A©óÅܧóª`®g¶g´Á«á¡A¥ç¥iºû«ù¤@©w¤ô·Ç (¦å²y®e¿n¤ñ¤¤¦ì¼Æ%¡GA´Á¶¡43%¡AB´Á¶¡43%¡AC´Á¶¡42%¡F¥Õ¦å²y¤¤¦ì¼ÆG/l¡GA´Á¶¡6.1¡AB´Á¶¡5.9¡AC´Á¶¡5.7¡F¦å¤pªO¤¤¦ì¼ÆG/l¡GA´Á¶¡246¡AB´Á¶¡211¡AC´Á¶¡204)¡CÅܧóª`®g¶g´Á«á¡A¤j³¡¤À¨ü¸ÕªÌµÊŦªø«×«O«ùéw¦b¥¿±`½d³ò¤º (¥§¡Ècm¡GA´Á¶¡11.4¡AB´Á¶¡8.3¡AC´Á¶¡10.3)¡C¦å²G«ü¼Ð¹F§¹¥þ¤ÏÀ³¨ü¸ÕªÌ¤ñ¨Ò¡GA´Á¶¡42%¡AB´Á¶¡55%¡AC´Á¶¡67 %¡F¦å²G«ü¼Ð¹F³¡¥÷¤ÏÀ³¨ü¸ÕªÌ¤ñ¨Ò¡GA´Á¶¡60%¡AB´Á¶¡71%¡AC´Á¶¡67 %¡C¹F¤À¤l«ü¼Ð¤ÏÀ³¨ü¸ÕªÌ¤ñ¨Ò¡GA´Á¶¡31%¡AB´Á¶¡42%¡AC´Á¶¡75%¡C´î¤Öª`®gÀW²v¤Î¾ãÅéÃĪ«¼ÉÅS¶q¡A¥i¥H´î¤Ö©Ò¦³¤£¨}¨Æ¥ó¥H¤ÎÃÄ«~¬ÛÃö¤£¨}¨Æ¥ó¤§µo¥Í²v(¤£¨}¨Æ¥ó¥§¡¼Æ¤ñ¤W¨C¶g¨C¤H¼ÉÅS¶q)¡GA´Á¶¡0.17/0.09¡AB´Á¶¡0.3/0.09¡AC´Á¶¡0.08/0.03¡C µ²½× ®Ú¾Ú¥»«e¤©ÊÁ{§É¸ÕÅç¹w¥ý©w¸q«ü¼Ð©Ò±o¤§ªì¨B¸ê®ÆÅã¥Ü¡A±µ¨ü¨C¨â¶gª`®gAOP2014¦Ó¤ÏÀ³¨}¦n¤§±wªÌ¡A¶i¤@¨B´î¤Ö¥ÎÃÄÀW²v¦Ü¨C¥|¶gª`®g¤@¦¸¬O¹ê»Ú¥i¦æªº¡C´î¤Öª`®gÀW²v¤£·|¾ÉP¥ÎÃĵL®Ä¡A¤Ï¦Ó¥i©úÅã´£°ª±wªÌ@¨ü©Ê¡C³Ì«á¡AJAK2°ò¦]Åܲ§¶q¥i«ùÄò°§CÅã¥Ü¤zÂZ¯Àªº¼ÉÅS®É¶¡¦Ó«D¤zÂZ¯Àªº¥ÎÃľ¯¶q¡A¬°»¤¾É¤À¤l¤ÏÀ³ªº«n¦]¼Æ¡C¥»½g³ø§i¤§µo²{¡A¾A¥i¤ä«ù¤zÂZ¯À£\¨ã¦³ªvÀøPV¦h«Àø®Ä¤§·§©À¡A¨Ò¦p¸û§C¿@«×¤§AOP2014¡A¨ã¦³ºû«ù»¤µo§K¬ÌºÊ±±¤§«ùÄò®ÄªG¡C ì¤å¥X³B https://ash.confex.com/ash/2014/webprogram/Paper73030.html |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2014/12/9 ¤W¤È 07:45:27²Ä 5 ½g¦^À³
|
ÃĵØÃÄP1101·sÃÄÀø®Ä¨Î ±N¥Ó½Ð±M§Q 2014-12-08 Áp¦X³ø °OªÌ©P¤p¥P¢¬§Y®É³ø¾É ¥þ²y³Ì¤jªº¦å²G¯e¯f¬ÛÃö¬ã¨s»PªvÀø²±·|¢w¢w¡u¬ü°ê¦å²G¸~½F¦~·|¡]ASH¡^¡v¡A©ó¬ü°ê®É¶¡12¤ë6¤é¦Ü9¤éµn³õ¡A¤µ¦~»P·|ªº±M·~¤H¤h¶W¹L¨â¸U¤H¡C ÃĵØÃĪí¥Ü¡A¥Ñ¼Ú¬w±Mºë¦å²G¯e¯fªvÀøªº¦X§@¹Ù¦ñAOP©t¨àÃĤ½¥q¥D¾ÉªºP1101·sÃÄ¡A¥Î©ó¨u¨£¯u©Ê¬õ¦å²y¼W¥Í¯g¡]PV¡^¯f±wªº¤HÅéÁ{§É¸ÕÅç¡AÄ~¥h¦~µoªíµ²ªG«á¡A¤µ¦~AOP¤½¥q¦bASH¦A¶i¤@¨B½T»{µoªí¡AP1101ªvÀøPV¯f¤HªºªvÀø¤è¦¡¡A¥i±q¨C¨â©P¬I¥´¤@¦¸¡A©µªø¦Ü¨C¥|©P¤@¦¸¡AÃÒ¹ê¥iªø®É¶¡ºû«ùÀø®Ä¡AÃĵØÂåÃĤwµÛ¤â±N¦¹¦¨ªG¥Ó½Ð·s±M§Q¡C ¤@¥¹P1101ªºªø®Ä¥Ø¼Ð®ÄªGÀò½T»{«á¡A±N¦³¾÷·|¦¨¬°¥þ²yªv¡PV¯e¯fªº²Ä¤@Ó·sÃÄ¡CAOP°õ¦æªøRudolf Widmann³Õ¤hªí¥Ü¡AP1101°Æ§@¥Î§C¡B¦w¥þ©Ê°ª¡B@¨ü©Ê¨Î¡A¥BP1101¤£¥u¯àªvÀø¯gª¬¡A¬Æ¦Ü¦³¥i¯àªv¡PV¯e¯f¡A¦¨¬°²Ä¤@Ó¥i¥H¡uªv¼Ð¤Sªv¥»¡vªº·sÃÄ¡C ÃĵØÃÄ«hªí¥Ü¡AP1101¬O¦Û¦æ¬ãµoªº·s¤@¥Nªø®Ä«¬»E¤A¤G¾J¤zÂZ¯À£\-2b¡A¥Dn¥Ñ³æ¤@²§ºcª«²Õ¦¨¡Aµ²ºc³æ¯Â¡A¦]¦¹¥Î©óPV±wªÌ¡A¥i¥H´î¤Öµ¹ÃĦ¸¼Æ¡B´£°ª±wªÌ±µ¨ü«×¡B§ï¶i¥ÎÃÄ¿í±q©Ê¨Ã¨ã¦³§ó¦nªºªø´ÁÀø®Ä¡CÁ`¸g²zªL°êÄÁ¨Ã«ü¥X¡AP1101·íªì´N³]p¥H¥|Ó¬P´Á¬I¥´¤@¦¸¬°¥Ø¼Ð¡A³o¤]¬O¹L¥h¤Q¾l¦~¨Ó¡A°ê»Ú¦U¤jÃļt¿n·¥°l¨Dªº¥Ø¼Ð¡A³z¹L¦¹¦¸ªº©µªø¸ÕÅç¡A²×©óÃÒ¹êP1101¯à¦¨¥\¹F¨ìªø´Á®ÄÀø¥Ø¼Ð¡A³o¬OPV ¯e¯f¥v¤Wªº«¤j¬ð¯}¡AÃĵØÂåÃıN¶i¤@¨B¥Ó½Ð¬ÛÃö±M§Q¡C ºI¦Ü¥Ø«e¬°¤î¡APV©|µL¦³®ÄªºªvÀø¤è¦¡¡A¬ü°êFDAÁö©ó2012¦~®ÖãªvÀøìµo©Ê°©ÅèÅÖºû¤Æ¡]PMF¡^ªºJakafi¤W¥«¡A¦ÓJakafi¤]©ó¤µ¦~®Öã¥Î©óªvÀøPV¡A¦ýJakafi¬°¤@Ó¤p¤À¤lÃĪ«¡A»PP1101©ÒÄݪº³J¥Õ½èÃĪ«ºØÃþ¤£¦P¡C ÃĵØÃĪí¥Ü¡A¨u¨£¯e¯f¥ÎÃĪº»ù¿ú©ù¶Q¡A¥Dn¾a«OÀI¤½¥qµ¹¥I¡A¦]¦¹¥Ø¼Ð¥«³õ±NÂê©wÂåÀø«OÀI¨î«×°·¥þ¡B«µø¥Í¬¡«~½è©M±wªÌÅv¯qªº¥ý¶i°ê®a¡A¦p¬ü°ê¡B¼Ú¬w¡B¤é¥»¡B¥xÆWµ¥¡C¨ä¤¤¡APV¦b¬ü°ê¯f¤H¼Æ¦ôp¬ù¦³15¸U¤H¡B¼Ú¬w¯f¤H¼Æªñ¹F20¸U¤H¡AY¥H¤@¦~ÃÄ»ù10¸U¬ü¤¸p¡A¼ç¦bªº¥«³õ°Ó¾÷¶W¹L¦Ê»õ¬ü¤¸¡C P1101¤wÀò¬ü°êFDA¤Î¼Ú·ùEMA¦P·N§@¬°ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯gªº©t¨à¯f¥ÎÃÄ¡A¥¼¨Ó¦b¬ü°ê¡B¼Ú¬w¥«³õ¥i¨É¦³7¦~¤Î10¦~ªº¿W½æÅv¡C¦¹¥~¡A¥Ñ©óP1101¾A¥Î©ó¦h¶µ¾AÀ³¯gªºªvÀø¡]§t¦UºØ¦å²G¯e¯f»PÀù¯gµ¥¡^¡A¥¿½Tªº¥«³õ°Ï¹j¤Î²£«~®t²§µ¦²¤¡A¥«³õµo®i¼ç¤O¨Î¡AÃĵØÃıĶ}µo¦h¶µ¾AÀ³¯g¨Ã¶iµ¦²¤¡A²£«~½u§¹¾ã¡A¥¼¨ÓÀç¹B°ª«×¦¨ªø¥i´Á¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/8 ¤U¤È 07:58:21²Ä 4 ½g¦^À³
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/10/15 ¤U¤È 05:09:22 P1101 Fundamentals unchanged, time delay of three months ........ Estimated Enrollment: 12 Study Start Date: August 2013 Estimated Study Completion Date: March 2016 Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure) ...... A. ¹wp§¹¦¨®É¶¡¡G¨Ì¾Ú¥Ø«e¦¬®×¶i«×¡AY¤@¤Á¶¶§Q³Ì§Ö¥i¦b104¦~¤U¥b¦~»¼¥æ·sÃÄ ¬dÅçµn°O¥Ó½Ð¡A¼f¬d¶i«×±Nµø¥DºÞ¾÷Ãö¦Ó©w¡C time had update. Estimated Enrollment: 256 Study Start Date: September 2013 Estimated Study Completion Date: September 2015 Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure) http://clinicaltrial.gov/ct2/show/NCT01949805?term=proud-pv&rank=2 |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/8 ¤U¤È 04:59:29²Ä 3 ½g¦^À³
|
¥»¸ê®Æ¥Ñ¡@(¿³Âd¤½¥q) ÃĵØÂåÃÄ¡@¤½¥q´£¨Ñ §Ç¸¹ 2 µo¨¥¤é´Á 103/12/08 µo¨¥®É¶¡ 16:05:26 µo¨¥¤H ªL°êÄÁ µo¨¥¤H¾ºÙ Á`¸g²z µo¨¥¤H¹q¸Ü 02-26557688 ¥D¦® ÃĵØÂåÃÄ·sÃÄP1101©ó¬ü°ê¦å²G¸~½F¦~·|µoªí¡GªvÀø¯u©Ê ¬õ¦å²y¼W¥Í¯g(PV)ªø®Ä®ÄªG½T»{¡A¹F¨ì¨CӤ르¤@°w¥B°Æ§@ ¥Î§ó§Cªº¥Ø¼Ð(§ó¥¿¹wp§¹¦¨®É¶¡) ²Å¦X±ø´Ú ¡@²Ä 42 ´Ú ¨Æ¹êµo¥Í¤é 103/12/08 »¡©ú 1.¨Æ¹êµo¥Í¤é:103/12/08 2.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¥»¤½¥qì³]pµo©úP1101®É¡A§Y¥H¨C¤G¦Ü¥|¶g¬I¥´¤@¦¸¬°¥Ø¼Ð¡C¥»¤é¡A¥»¤½¥q±ÂÅv¹Ù¦ñ ¶ø¦a§QAOP¤½¥q©ó¬ü°ê¦å²G¸~½F¦~·|(ASH MEETING)¤¤µoªíP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W ¥Í¯g(PV)¤§©µªøÁ{§É¸ÕÅç³ø§i¡A¸Ó¸ÕÅç³]p±N¨C¨â¶gµ¹ÃĤ@¦¸¥BÀø®Ä¨}¦nªºPV±wªÌ¡A ¦bªvÀø¤@¦~«á½Õ¾ã¦Ü¨C¥|¶gµ¹ÃĤ@¦¸¡A¨ä¤¤³¡¤À¸ÕÅç±wªÌ¤w«ùÄòÀøµ{ªø¹F¥|¦~¡C¸g¦¹ ½Õ¾ã«á¡A±wªÌ¦å²G¤¤¬õ¦å²y«ü¼Æ¤´ºû«ù¦b¥¿±`ª¬ºA¡A¥iª¾·s¤@¥Nªºªø®Ä«¬¤zÂZ¯À±µ¨ü «×§ó¦n¡C¸ÓÁ{§É¸ÕÅç³ø§iÃÒ¹êP1101¨C¤G¦Ü¥|¶gµ¹ÃĤ@¦¸ªºªvÀø¤è¦¡½T¹ê¥i¦æ¡A³o¤]¥¿ ¬O¥þ²yÃĬɤ@ª½¥H¨Ó¿n·¥°l¨Dªº¥Ø¼Ð¡C 6.¦]À³±¹¬I:µo¥¬¥»«¤j°T®§ 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: (1)¬ãµo·sÃÄ¥N¸¹©Î¦WºÙ¡GP1101 (2)¥Î³~¡GP1101«Y·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\2b)¡A²{¥¿¶i¦æ¥Î©óªv Àø¯u©Ê¬õ¦å²y¼W¥Í¯gµ¥¤HÅéÁ{§É¸ÕÅç (3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G²Ä¤T´ÁÁ{§É¸ÕÅç(Pivotal Trial)¡B·sÃĬdÅçµn°O¥Ó½Ð (Biologics License Application) (4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G ªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\2b)(P1101)ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g±wªÌªº ¥þ²y©Ê²Ä¤T´ÁÁ{§É¸ÕÅç(Pivotal Trial)¡A¸ÕÅ粺ÙPROUD-PV¡A¸ÓÁ{§É¸ÕÅç²{ ¥¿¶i¦æ¤¤¡C ºô§}³sµ²: http://clinicaltrial.gov/ct2/show/NCT01949805?term=proud-pv&rank=2 (¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î (¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î (¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡GPROUD-PV©ó¼Ú¬w¶i¦æ¤§Á{§É¸ÕÅç¸g¶O¡A«Y¥þ¼Æ¥Ñ¥» ¤½¥q±ÂÅv(out-licensing)¹Ù¦ñ¶ø¦a§QAOP¤½¥q¤ä¥I¡C (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G P1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅ秹¦¨«á¡A±N¦V¬ü°êFDA¤Î¼Ú¬wEMA »¼¥æ·sÃĬdÅçµn°O¥Ó½Ð(Biologics License Application)¡C A.¹wp§¹¦¨®É¶¡¡G¨Ì¾Ú¥Ø«e¦¬®×¶i«×¡AY¤@¤Á¶¶§Q³Ì§Ö¥i¦b104¦~¤U¥b¦~»¼¥æ·sÃÄ ¬dÅçµn°O¥Ó½Ð¡A¼f¬d¶i«×±Nµø¥DºÞ¾÷Ãö¦Ó©w¡C B.¹wpÀ³t¾á¤§¸q°È¡G¥»¤½¥q±Nt³d¦V¬ü°êFDA»¼¥æ·sÃĬdÅçµn°O¥Ó½Ð¡F¼Ú¬w¦a°Ï «h¥Ñ¥»¤½¥q±ÂÅv¹Ù¦ñAOP¤½¥qt³d¦VEMA¥Ó½Ð¡C (6)·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G¤p^10137462 µoªí®É¶¡:2014/12/8 ¤U¤È 04:37:04²Ä 2 ½g¦^À³
|
³Ìªñ¶q¼W»ùº¦¤§ì¦]. ....... http://www.ttv.com.tw/103/12/1031208/122014081513EB289A6BE2704A3A8E8570824A91D2B1B5C8.htm ÃĵØÂåÃÄ¡GÃĵØÂåÃÄ·sÃÄP1101©ó¬ü°ê¦å²G¸~½F¦~·|µoªí¡GªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g(PV)ªø®Ä®ÄªG½T»{¡A¹F¨ì¨CӤ르¤@°w¥B°Æ§@¥Î§ó§Cªº¥Ø¼Ð ²Ä¤T¤Q¥|±ø¡@²Ä42´Ú1.¨Æ¹êµo¥Í¤é:103/12/082.¤½¥q¦WºÙ:ÃĵØÂåÃĪѥ÷¦³¤½¥q3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©ÎÁpÄݤ½¥q):¥»¤½¥q4.¬Û¤¬«ùªÑ¤ñ¨Ò(Y«e¶µ¬°¥»¤½¥q¡A½Ð¶ñ¤£¾A¥Î):¤£¾A¥Î5.µo¥Í½t¥Ñ: ¥»¤½¥qì³]pµo©úP1101®É¡A§Y¥H¨C¤G¦Ü¥|¶g¬I¥´¤@¦¸¬°¥Ø¼Ð¡C ¥»¤é¡A¥»¤½¥q±ÂÅv¹Ù¦ñ ¶ø¦a§QAOP¤½¥q©ó¬ü°ê¦å²G¸~½F¦~·|(ASH MEETING)¤¤µoªíP1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W ¥Í¯g(PV)¤§©µªøÁ{§É¸ÕÅç³ø§i¡A¸Ó¸ÕÅç³]p±N¨C¨â¶gµ¹ÃĤ@¦¸¥BÀø®Ä¨}¦nªºPV±wªÌ¡A ¦bªvÀø¤@¦~«á½Õ¾ã¦Ü¨C¥|¶gµ¹ÃĤ@¦¸¡A¨ä¤¤³¡¤À¸ÕÅç±wªÌ¤w«ùÄòÀøµ{ªø¹F¥|¦~¡C ¸g¦¹ ½Õ¾ã«á¡A±wªÌ¦å²G¤¤¬õ¦å²y«ü¼Æ¤´ºû«ù¦b¥¿±`ª¬ºA¡A¥iª¾·s¤@¥Nªºªø®Ä«¬¤zÂZ¯À±µ¨ü «×§ó¦n¡C ¸ÓÁ{§É¸ÕÅç³ø§iÃÒ¹êP1101¨C¤G¦Ü¥|¶gµ¹ÃĤ@¦¸ªºªvÀø¤è¦¡½T¹ê¥i¦æ¡A³o¤]¥¿ ¬O¥þ²yÃĬɤ@ª½¥H¨Ó¿n·¥°l¨Dªº¥Ø¼Ð¡C 6.¦]À³±¹¬I:µo¥¬¥»«¤j°T®§7.¨ä¥LÀ³±Ô©ú¨Æ¶µ:(1)¬ãµo·sÃÄ¥N¸¹©Î¦WºÙ¡GP1101(2)¥Î³~¡GP1101«Y·s¤@¥NPEGªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\2b)¡A²{¥¿¶i¦æ¥Î©óªv Àø¯u©Ê¬õ¦å²y¼W¥Í¯gµ¥¤HÅéÁ{§É¸ÕÅç(3)¹wp¶i¦æ¤§©Ò¦³¬ãµo¶¥¬q¡G²Ä¤T´ÁÁ{§É¸ÕÅç(Pivotal Trial)¡B·sÃĬdÅçµn°O¥Ó½Ð (Biologics License Application)(4)¥Ø«e¶i¦æ¤¤¤§¬ãµo¶¥¬q¡G (¤@)´£¥X¥Ó½Ð/³q¹L®Öã/¤£³q¹L®Öã¡G ªø®Ä«¬£\¤zÂZ¯ÀÃĪ«(PEG-P-IFN-£\2b)(P1101)ªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g±wªÌªº ¥þ²y©Ê²Ä¤T´ÁÁ{§É¸ÕÅç(Pivotal Trial)¡A¸ÕÅ粺ÙPROUD-PV¡A¸ÓÁ{§É¸ÕÅç²{ ¥¿¶i¦æ¤¤¡C ºô§}³sµ²: http://clinicaltrial.gov/ct2/show/NCT01949805?term=proud-pv&rank=2 (¤G)¥¼³q¹L¥Øªº¨Æ·~¥DºÞ¾÷Ãö³\¥iªÌ¡A¤½¥q©Ò±Á{¤§·ÀI¤Î¦]À³±¹¬I¡G¤£¾A¥Î (¤T)¤w³q¹L¥Øªº¨Æ·~¥DºÞ³\¥iªÌ¡A¥¼¨Ó¸gÀç¤è¦V¡G¤£¾A¥Î (¥|)¤w§ë¤J¤§²Ö¿n¬ãµo¶O¥Î¡GPROUD-PV©ó¼Ú¬w¶i¦æ¤§Á{§É¸ÕÅç¸g¶O¡A«Y¥þ¼Æ¥Ñ¥» ¤½¥q±ÂÅv(out-licensing)¹Ù¦ñ¶ø¦a§QAOP¤½¥q¤ä¥I¡C (5)±N¦A¶i¦æ¤§¤U¤@¬ãµo¶¥¬q¡G P1101¥Î©óªvÀø¯u©Ê¬õ¦å²y¼W¥Í¯g²Ä¤T´ÁÁ{§É¸ÕÅ秹¦¨«á¡A±N¦V¬ü°êFDA¤Î¼Ú¬wEMA »¼¥æ·sÃĬdÅçµn°O¥Ó½Ð(Biologics License Application)¡C A.¹wp§¹¦¨®É¶¡¡G¨Ì¾Ú¥Ø«e¦¬®×¶i«×¡AY¤@¤Á¶¶§Q³Ì§Ö¥i¦b105¦~¤U¥b¦~»¼¥æ·sÃÄ ¬dÅçµn°O¥Ó½Ð¡A¼f¬d¶i«×±Nµø¥DºÞ¾÷Ãö¦Ó©w¡C B.¹wpÀ³t¾á¤§¸q°È¡G¥»¤½¥q±Nt³d¦V¬ü°êFDA»¼¥æ·sÃĬdÅçµn°O¥Ó½Ð¡F¼Ú¬w¦a°Ï «h¥Ñ¥»¤½¥q±ÂÅv¹Ù¦ñAOP¤½¥qt³d¦VEMA¥Ó½Ð¡C (6)·sÃĶ}µo®Éµ{ªø¡B§ë¤J¸g¶O°ª¥B¨Ã¥¼«OÃÒ¯à¤@©w¦¨¥\¡A¦¹µ¥¥i¯à¨Ï§ë¸ê±Á{·ÀI¡A §ë¸ê¤HÀ³¼f·V§PÂ_ÂÔ·V§ë¸ê¡C |
|
|
·|û¡G·Æ½ü8ªÎ10136452 µoªí®É¶¡:2014/12/8 ¤U¤È 04:11:43²Ä 1 ½g¦^À³
|
ÃÒ´Á·|ºô¯¸¤½§i»~Ȭ°105¦~¤U¥b¦~°e¥ó¬O¿ùªº,¤w¸ò¤½¥q½T»{...¤D¬O2015¤U¥b¦~ |
|
|
|